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MRCK is a downstream effector of Cdc42, a member of Rho GTPase and its main 
function is in regulating cytoskeletal reorganization. Upon binding to Cdc42-GTP, it is 
activated and its subsequent signalling mechanisms are turned on through multiple 
phosphorylation events. The regulation of MRCK activity and its binding partner(s) have 
recently been studied and unravelled. One of the most important roles of MRCK is in the 
regulation of lamellar actomyosin retrograde flow which is intimately linked to membrane 
protrusion at the leading edge in migrating cells and involved in directional cell motility. 
Owing to the significant functions of MRCK, studies regarding detection of MRCK by 
aptamers and inhibition of MRCK by chemical compounds were highlighted in this project.  
Aptmers are short sequences of RNA/DNA which can form secondary structure and 
have binding capacity to various molecules including proteins. As such, they have been used 
as molecular probes for detection purposes and they may also have therapeutic potential. Here 
a screening process called systematic evolution of ligands by exponential enrichment (SELEX) 
that coupled with subsequent separation of aptamers by capillary electrophoresis (CE) was 
carried to identify specific MRCK aptamers. By performing CE-SELEX, MRCK aptamers 
were selected from a single stranded DNA (ssDNA) library consists of 40-mer random 
sequences. Non-SELEX, one of the protocols for performing CE-SELEX, omits DNA 
amplification and was used for selection. Owing to the novelty of this protocol, method 
development has been studied in detail for future work. A number of optimizations and 
adjustments were tested in order to improve the selection efficiency and quality. The original 
non-SELEX method and a modified non-SELEX method were used for selection in a 
comparative study. MRCK aptamers with dissociation constant (Kd) of about 100 nM were 
obtained from both methods. One of the aptamers, M6, was able to detect the active form of 
MRCK kinase domain but not the inactive form. Subsequently, MRCK binding affinity of 
  
v
these two aptamers was further confirmed by demonstrating in vitro binding analysis with CE 
and an in vitro MRCK pull down assay. 
Our initial interest was to identify aptamers that can inhibit MRCK. Nonetheless, no 
successful result was obtained from the selected aptamers. Therefore, a screen for chemical 
inhibitor of MRCK was concurrently implemented as the second part of this project. To 
search for a selective MRCK chemical inhibitor, screening for MRCK inhibitors from a group 
of chemicals was carried out. A total of about 170 chemicals were screened with an in vitro 
kinase assay. Chelerythrine chloride (che/chelerythrine) was identified from these compounds 
to have MRCK inhibitory effect. Its half maximal inhibitory concentration (IC50) was later 
confirmed to be 0.86 µM by radioactive kinase assay. A much weaker inhibitory effects were 
observed on the related Rho Kinase and Citron Kinase with an IC50 of 8.6 µM and 6.4 µM 
respectively. At a concentration of 5 µM, chelerythrine was able to perturb MRCK 
localization in HeLa cells. Reduced cell migration was also observed in chelerythrine 
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Chapter 1 Introduction 
Section 1 Screening of aptamers for myotonic dystrophy kinase-related Cdc42 binding 
kinase (MRCK) by CE-SELEX 
 
1.1.1 Overview 
Specific and effective protein detection is of vital importance in disease diagnoses and 
treatments. In addition, specific recognition of proteins is useful for the studies of protein 
function. It is therefore a need to generate protein detection methods with high specificity and 
efficiency. Commercially available antibodies specific for a wide variety of target protein are 
useful for both medical and scientific research. They are widely used in protein detection 
probes such as Western blot analysis and diagnoses. Some antibodies have even been tested in 
clinical trials and have received approval for disease treatments. For example muromonab-
CD3, a monoclonal antibody, was the first antibody to be approved in 1986 as transplant 
rejection drug (62); Eculizumab, a humanized monoclonal antibody, was approved two years 
ago for the treatment of paroxysmal nocturnal hemoclobunuria (35).   
Although antibodies have been very useful on monitoring of protein localization 
intracellularly, the problem of high background noise due to cross reactivity has been 
associated with its usage. In addition, the fluorescent signal of antibodies is constitutive that it 
does not change upon binding to the target. Furthermore, the whole process of antibody 
production is time consuming and costly. Its production also requires sacrifice of the 
immunized animals, a step when implicates ethic issues that should be avoided is possible. 
Consequently, a rapid and not hazardous method to generate a low cost tool for protein 
detection is of high demand and interest. 
A relatively new protein detection tool, aptamer, is introduced here. Aptamers are short 
sequences of either DNA or RNA and with binding capacity to various types of targets, such 
as ions, proteins and small molecules (ATP, antibiotics, etc.). They have the potential to be 
used as effective molecular probes for the purpose of detecting and recognizing important 
biological targets. In order to select aptamers for a particular target, performing a screening 
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experiment is required. Systematic evolution of ligands by exponential enrichment (SELEX) 
is a screening technique that allows rapid selection and enrichment of specific ligands via 
repeated rounds of partition and amplification from a large combinatorial nucleic acid library 
(4). New SELEX approach using capillary electrophoresis (CE) has been exploited in this 
project as a quick and easy way to obtain specific aptamers for a particular target.  
 
1.1.2 Aptamers 
As aforementioned, aptamers are generated by an in vitro selection process, SELEX, 
from random sequences of DNA or RNA libraries.  They are similar to antibodies in terms of 
their protein binding capacity. They can be isolated rapidly in vitro and have been shown not 
to elicit an immune response in the human body (13). Aptamers could be regenerated easily 
after denaturation. They are stable in long-term storage and can be transported at ambient 
temperature. Therefore, aptamers have distinct advantages over other reagents of being 
utilized as diagnostic, analytical and potential therapeutic agents (14). Moreover, aptamer can 
even be engineered into oligonucleotide probe called molecular aptamer beacon (MAB) that 
aids in protein detection. 
 Aptamers, as single-stranded oligonucleotides, have diverse biological functions and 
applications due to their ability to fold into three-dimensional shapes of flexible structure and 
form “pocket” structure which can bind to various target molecules, including proteins, small-
molecule compounds, and even living cells (26, 102). Furthermore, DNA or RNA aptamers 
with the length of 40 random bases, for example, can give up to 1024 of different sequences.  
This enables them to have potentially diverse conformational structures and thus provides a 
higher probability to have at least one species that possesses high affinity to a target of 
interest (30).   
 
1.1.2.1 The applications of aptamers 
As a consequence of the specific affinity and binding capacity of aptamers, numerous 
applications of aptamers are attributed. The major applications include pharmacological 
2 
 
probes as biosensors for in vivo and in vitro target validation (9, 90), intracellular probes for 
protein function analysis and drug discovery (25, 57), development of biosensors, small-
molecule lead compounds for enzyme and receptor inhibition (17, 68), ligands for affinity 
chromatography and capillary electrophoresis (72), molecular probes for in vivo imaging (95), 
and candidate therapeutics for disease healing (15).  
Pegaptanib (vascular endothelial growth factor aptamer, Macugen) is a modified RNA 
aptamer, consists of 28 nucleotides, which can specifically bind to extracellular vascular 
endothelial growth factor (VEGF) and inhibits VEGF (76). It prevents VEGF from interacting 
with its receptor on the surface of vascular endothelial cells and results in pathological 
angiogenesis suppression. Recently, this RNA aptamer has already received approval for the 
treatment of age-related macular degeneration (97). The inhibition of Pegaptanib in the 
interaction of VEGF with its receptors attributes to its potential for the treatment of diabetic 
retinopathy and it is now undergoing clinical trials to assess its treatment on this disease (19).  
Meanwhile, there are also several other aptamers undergoing clinical trials and development 
into drug candidates. These potential aptamer-based drugs are aptamers against 
amyloidogenic proteins such as the Aβ-peptide associated with Alzheimer disease (106), and 
aptamers against abnormal proteins found in prion disease (79).   
Furthermore, the selectivity of aptamers makes them ideal to be developed into 
diagnostic reagents with conformational changes upon binding to ligand. In fact, aptamers 
have been modified and engineered into nucleic acid MAB that possesses a stem-loop 
structure. The loop sequence of MAB serves as a probe that is complementary to the target 
sequence, and the annealing of two complementary arm sequences forms the stem. The 
detection of the MAB is performed by either differential fluorescence quenching or 
fluorescence resonance energy transfer (FRET). The hairpin shaped MB, when encounters a 
target molecule, will form a probe-target hybrid that is more stable than the stem in the 
hairpin. This results in conformational changes and the stem-loop structure is open up to 
permit the release of fluorescent or FRET signal (Fig. 1.1).  This feature makes MAB an 
extremely useful probe in monitoring protein in real time and in homogenous solution.  It has 
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Fig. 1.1 The working model of a MAB binding to its protein target. The flourophore of a 
hairpin-structured MAB is quenched and gives no signal when it is not bound to the target.  
Interaction of MAB to its target opens up the MAB and releases the fluorescent signal. 
1.1.2.2 The advantages and disadvantages of aptamers 
Although aptamers have equivalent function as antibodies in recognizing target proteins, 
aptamers have a few advantages over antibodies. Aptamers can recognize the functional 
domains of proteins, such as catalytic domain of a protein, and thereby might be used in 
regulating the target’s biological functions. In fact, a good aptamer can even distinguish 
between wild type and mutant protein or between active and inactive proteins or between 
different conformational states of a single molecule(14). Moreover, aptamers can be modified 
to be more useful in executing their functions, for example aptamers are immobilized onto to 
a solid support to form affinity column, bioengineered with fluorophore or quencher tag at 
either end for live cells imaging, and attached with appropriate functional groups for 
deliverance into living cells or animals. Despite the modifications, their target-recognition 
properties are still well preserved. As mentioned previously, aptamers are indeed rather safe in 
developing into therapeutic agents due to their lack of immunogenicity. In contrast, antibodies 
are often immunogenic and might not be as ideal as aptamers in exhibiting therapeutic 
functions. One of the most important benefits of aptamers, as compared to antibodies, is their 
remarkable stable properties in term of shelf life. They are more resistant towards temperature 
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changes and are thus easier to handle. Consequently, they have great potential in being 
exploited for the application in pharmacological areas. 
However, as aptamers are more prone to be degraded by endogenous endonucleases and 
exonucleuses, research to overcome such a problem needs to be addressed. In fact, the 
aptamer structure is chemically modified to render it more stable for resistance towards 
generic nucleases to increase half-life of the aptamer (69). For example, Pegatapnib was 
indeed modified at the 2’position in several residues with F in pyrimidine bases or methoxy in 
purine bases to replace the natural OH groups in the RNA sequences.   
 
1.1.3 The selection of aptamer 
SELEX is the most versatile and common method to select nucleic acid aptamers for a 
target. It was first reported in 1990 by Gold’s group (93) to study the interaction between a T4 
DNA polymerase and mRNA, and Szostak (23) to isolate RNA molecules that bind 
specifically to a variety of organic dyes. Later on, it was subsequently developed into a 
technology for in vitro selection of specific aptamers for a chosen target from a random pool 
of DNA or RNA library (58). This method starts from an automated chemical generated 
random library of DNA or RNA molecules. The three main procedures are shown in Fig. 1.2 
and the details of SELEX are as below: 
1. Selection 
A library of nucleotide sequences is incubated with the target for a given period of time. 
The molecules in the library without affinity to the target will remain free in the solution 
while those with affinity to the target will be bound to the target. Target-bound and unbound 
molecules can be separated by using various techniques, such as affinity chromatography, 
membrane filter, capillary electrophoresis, and etc.  Finally, aptamers with higher affinity to 
the target will be eluted or collected from the target and they will form into an enriched pool 
of DNA for the subsequent steps. 
2. Amplification 
The collected and purified sequences are amplified by polymerase chain reaction (PCR) to 
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yield a pool of aptamers that binds to target with higher affinity. This enriched pool generated 
from the PCR-amplified sequences is used for the next round of selection, partition and 
amplification. 
3. Aptamer isolation 
In some cases, the selection conditions are changed to more stringent conditions to allow 
purification of tight and specific binders only. Selection and amplification procedures will be 
repeated for several rounds till the enriched library achieves a certain level of bulk affinity. 
After that, individual aptamer sequences from the enriched library are selected and identified 
by molecular cloning and DNA sequencing. Lastly, the individual aptamers are chemically 





Fig. 1.2 The three main processes which are involved in SELEX. Random sequences of 
DNA/RNA library is incubated with the target; various partitioning techniques, such as 
membrane filter, affinity column or titer plate, are used for partitioning of target-bound 
aptamers from non aptamers; the selected aptamers are regenerated by PCR amplification 
for the next round of selection. (Adapted from Yang Y et al. (104)) 
 
1.1.3.1 Capillary electrophoresis (CE) as a technique for SELEX 
The conventional approach of SELEX was done by passing the aptamers through a 
column with target molecules immobilized on a stationary support by a linker molecule. The 
linker might also form steric hindrance on some parts of the target and might prevent the 
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aptamers to have complete access towards the target. Moreover, this method requires a 
blocking step and it is generally difficult to recover strong target binders from the column 
(44). In contrast, membrane filtration method, normally used for large SELEX targets like 
proteins, allows aptamers to interact freely with target in solution and eliminates linker bias 
(34). Unfortunately, both column purification and membrane filtration processes require 10-
15 cycles of selections to obtain high-affinity aptamers. To overcome this problem, a modified 
technique, CE, has been utilized as an alternative enrichment method for improving the 
efficiency of selection in the SELEX procedure. CE was designed to separate samples based 
on their size to charge ratio in the interior of a small capillary filled with an electrolyte using 
electrical field (Fig. 1.3). One major advantage of CE is that only a small volume of sample in 
nanoliter range is required. In brief, CE-SELEX applies electrophoresis principle to separate 
aptamer-target binding complexes from free aptamers. A library of aptamers is incubated with 
the target first before they are injected into a capillary. Separation is done in the capillary, 
which is filled with running buffer, with electrical polarity applied at the two ends. Specific 
binders are separated from nonbinding molecules based on a mobility shift induced by the 
formation of aptamer-target complexes (33)(Fig. 1.4). In principle, the modern CE technology 









Fig. 1.3 A diagram of capillary electrophoresis system. The main components of the 
system contain source and destination vials, a sample vial, a capillary, electrodes, a high-
voltage power supply, a detector, and a data output. The source vial, destination vial and 
capillary are filled with an electrolyte such as an aqueous buffer solution. Normally, anode is 



























Fig. 1.4 The complete procedures of aptmers selection using CE-SELEX. The nucleic 
acid library is incubated and mixed with the target protein. The mixtures are injected into 
the CE and separated in a free solution. Same as conventional SELEX, binding sequences 
are partitioned from nonbinding sequences based on a mobility shift induced by the 
formation of aptmer-target complexes.  Collected sequences are PCR amplified to generate 
a new pool for further rounds of selections.  
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1.1.4 CE partitioning methods: NECEEM and ECEEM 
Two types of partitioning process have been recently introduced for CE-SELEX: 
nonequilibrium capillary electrophoresis of equilibrium mixtures (NECEEM) and equilibrium 
capillary electrophoresis of equilibrium mixtures (ECEEM).   
NECEEM is an approach in which the equilibrium fraction of target-bound DNA is 
partitioned from the equilibrium mixture of free DNA without having components of the 
DNA library or the target in the running buffer (Fig. 1.5). As a result, complexes with weak 
interaction tend to dissociate during their migration along the capillary while binders with 
high affinity to the target are eventually selected. NECEEM was claimed to be more advanced 
than conventional SELEX methods in three aspects: (i) high efficiency of aptamer selection, 
(ii) accurate determination of binding parameters (e.g. dissociation constant, Kd), and (iii) 
capable to quantitate targets with their aptamers. Berezovski M et al. (5) even demonstrated 
that a single round of NECEEM-based SELEX was sufficient for obtaining a pool of aptamers 
for PFTase with Kd in the range of 1 nM (5), in contrast to conventional methods which 
require 8-12 rounds. Bowser’s group also successfully selected a pool of high-affinity DNA 
aptamers for human IgE and HIV-1 reverse transcriptase (HIV-1 RT) using NECEEM. The 
average Kd of the sequences in the enriched pool for IgE was in nanomolar range (60) and 
picomolar affinity for HIV-1 RT (64) after 4 rounds of selection. Moreover, they proved that 
NECEEM is applicable in isolating aptamers for targets smaller than the DNA sequences by 
performing 80-mer aptamers (~25kDa) selection against neuropeptide Y (NPY)(~4kDa). It is 
much simpler to select aptamers for high molecular weight targets because they retard the 
mobility of DNA upon binding. Though the mobility of a DNA sequence only changed 
slightly upon binding to NPY, enriched pool in low nanomolar Kd was obtained when they 
performed three CE collections for every round of selection to increase the number of DNA 
sequences for partition (59). High-affinity DNA aptamers for Protein kinase C δ (PKCδ) have 
also been selected using NECEEM. Nine rounds of selection, which the others only did 3-4 
rounds, were carried out and the lowest Kd of the aptamer-protein binding is 122 nM (55). 
Last but not least, DNA aptamers that specifically recognize ricin toxin were selected with 
9 
 
NECEEM and the enrichment achieved 87.2% purity (based on percentage of bound aptamers) 
after 4 rounds of selection. The aptamers derived were found to possess high affinity and 















Fig. 1.5 Schematic representation of NECEE-based selection of DNA aptamers. (a)The 
equilibrium mixture (EM) consists of free DNA, DNA-target complex (DNA.T), and free 
target (T). (b)NECEEM-based separation of the EM. Target-bound DNA (red) is separated 
from the free DNA (green). Here shows the spatial distribution of the separated components 
in the capillary at different times (t0=0, t2>t1>t0) from the beginning of separation. (Adapted 
from Berezovski M et al. (5)) 
As for ECEEM, in which aptamer-target equilibrium is maintained during 
partitioning, it is able to select aptamers with predefined values of Kd (21) . This method, 
however, required target presence in the running buffer at the concentration equal to that of 
the target concentration in the equilibrium mixture and this will increase target consumption 
in comparison with NECEEM. Moreover, the completion of ECEEM requires NECEEM to 
determine the migration times of complexes and free aptamers, and Kd values as well. 
ECEEM combined with NECEEM was reported in aptamer selection for MutS and the best 
candidate selected had an affinity of 3.6nM±0.5nM (22). Three rounds of ECEEM-based 
selection were performed to develop aptamers with predefined Kd and NECEEM to find out 





Non-SELEX is a modified CE-SELEX technique which employs NECEEM-based 
partitioning, with enhanced efficiency by excluding the steps of PCR amplification in 
between rounds of selection. Fig. 1.6 depicts the difference between conventional SELEX and 
non-SELEX while Fig. 1.7 describes the procedures of non-SELEX. Non-SELEX has at least 
two advantages over SELEX: (i) more rounds of aptamer selection can be done in one day, 
and (ii) aptamer selection can be performed in an automated fashion using a commercially 
available CE instrument (6). For better understanding to these distinct methodologies, the 
similarities and differences of conventional SELEX, CE-SELEX and non-SELEX were 
summarized in Table 8 (Appendix). In a proof-of-principle work, aptamers for h-Ras were 
partitioned via non-SELEX. Three rounds of non-SELEX were able to generate an enriched 
pool of DNA with average 300nM Kd value.  
 
1.1.6 Aim of research 
CE-SELEX is a novel technique which can be applied to aptamer selection for any 
target of interest. As CE-SELEX is still in its infancy, careful optimization and development 
of this technique is required for proper selection of aptamers. The main objective of this study 
is to optimize the CE selection method and conditions for the selectiong of aptamers specific 
to our protein of interest, MRCK. Subsequently, the binding ability of the selected aptamers is 


















Fig. 1.6 Schematic of the differences between SELEX and non-SELEX procedures. 
The only difference between SELEX and non-SELEX is that the step of amplification is 
















Fig. 1.7 Diagram shows all the procedures of a complete set of aptamer selection 
using non-SELEX method. Three steps of NECEEM-based partitioning are involved in 





Section 2 Screening of selective inhibitors for myotonic dystrophy kinase-related Cdc42 
binding kinase (MRCK) by chemical inhibition 
 
1.2.1 Overview 
Cell migration is an essential event that takes place throughout the entire lifespan of 
all multicellular organisms. Rho family of GTPases was found to play a central role in this 
process through their regulation on cytoskeletal reorganization. The functions of Rho, Rac 
and Cdc42 have especially been well established over the past decades. In brief, Cdc42 
regulates the direction of migration, Rac induces membrane protrusion at the front edge of the 
cell via actin polymerization and integrin adhesion complexes, and Rho promotes actomyosin 
contraction in the cell body and at the rear. These GTPases act as molecular switches via their 
respective sets of downstream effector proteins in the regulation of cell motility and 
cytoskeletal changes. 
MRCK, a Rac/Cdc42-binding kinase, was reported to function downstream of Cdc42 
in regulating cytoskeletal reorganization and lamellar actomyosin retrograde flow, which is 
crucial to membrane protrusion and cell migration. MRCK inhibition therefore could result in 
cell motility inhibition. However, no known selective MRCK inhibitor is available. Thus, it is 
of our interest to screen and identify such inhibitors. In an initial screen performed in this 
project, around 170 chemicals were screened for this ability to inhibit MRCK. The highest hit 
was obtained from a compound named chelerythrine chloride. It was shown to inhibit MRCK 
activity an with IC50 of 0.86 µM while it only inhibits Rho-associated kinase (ROK) and 
Citron Rho-interacting kinase (CRIK) at higher concentrations. The IC50 for ROK and CRIK 
are 8.6 µM and 6.5 µM respectively. Chelerythrine chloride, at a concentration of 5 µM, was 
able to perturb MRCK localization in the cells and results in a reduced cell migration rate in 
U2OS cells using wound healing assay. 
 
1.2.2 Cell migration and Rho GTPase 
Cell migration is an event that can be observed in wound healing, immune 
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surveillance, and also during the growth and development of multicellular organisms. In fact, 
cell migration is mainly controlled by internal and external signals, such as attractants or 
repellents from distant environment, neighboring cells or extracellular matrix (ECM) (71). 
These signals in turn activate complex signal transduction cascades that result in highly 
dynamic changes in actomyosin cytoskeleton, microtubules, vesicular transport pathways, 
genes transcription and protein-protein interaction. Actomyosin cytoskeleton, microtubule 
system with motors, and also intermediate filament system, coordinate with each other like an 
orchestra to modulate the whole process of cell movement (20).  
A huge variety of intracellular signaling molecules has been implicated in cell 
migration, including MAPK cascades, lipid kinases, phospholipases, serine/threonine and 
tyrosine kinases and scaffold proteins. Rho GTPase as one particular family of proteins seems 
to play a pivotal role in regulating the biochemical pathways most relevant to cell migration. 
Therefore, Rho GTPase is believed to be one of the key contributions that regulate the process 
of cell migration. 
The Ras-related Rho family of GTPases is constituted with small signaling G proteins 
which are usually 21 kDa. The primary roles of Rho GTPases include regulating the actin 
cytoskeleton, cell polarity, microtubule dynamics, membrane transportation and transcription 
factor activity. These low molecular weight GTPases act as molecular switch to control 
complex cellular processes by shuttling between two conformational states, the inactive GDP-
bound form and the active GTP-bound form. The GTP-bound Rho GTPases interact with their 
respective downstream effectors to generate a response till they hydrolyse GTP to GDP; the 
GDP-bound Rho GTPases are inactive and can be extracted from the membranes by guanine 
dissociation inhibitors (GDI). This cycle process, as shown in Fig. 1.8, is tightly regulated by 
guanine exchange factors (GEFs), GTPase activating proteins (GAPs), and GDIs.  Sixty 
effectors of Rho GTPases have been identified so far in which Rho, Rac and Cdc42 are the 
three best-characterized target proteins. 
The widely accepted model of cell migration is shown in Fig. 1.9. It is a cyclic 
process which initiates from a migration-induced signal. This signal activates Rac in 
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promoting actin polymerization to form peripheral lamellipodial protrusions (73) while Cdc42 
stimulates cell polarization in the front of the cells (24) and also caused the formation of 
actin-rich membrane extension structures called filopodia (47, 67).  Actin polymerization 
provides driving force for the extension of protrusions in the direction of migration while 
contraction, promoted by Rho, happens at the cell body and the back of the cell (73). These 
protrusions are stabilized by ECM or adjacent cells via formation of new focal adhesion or 
transmembrane receptors linked to the actin cytoskeleton. As the cell moves forward, the 









Fig. 1.8 The Rho GTPase cycle. Rho GTPases cycle between an inactive GDP-bound and an 
active GTP-bound conformation. Guanine nucleotide exchange factors (GEFs), when activated 
by upstream signals, can cause exchange of GDP to GTP and lead to activation of Rho GTPases. 
Active Rho-GTPs then interacts with their downstream effectors. GTPase activating proteins 
(GAPs) enhance GTP hydrolysis and inactivate Rho GTPases. Meanwhile, guanine dissociation 






Fig. 1.9 A schematic of the three stages of cell movement. An external migration-induced 
signal, sensed by the cell, determines the direction of cell motion. The cell then extends a 
protrusion in this direction by actin polymerization at the leading edge. It adheres its leading 
edge to the surface on which it is moving and detaches at the cell body and the rear. Finally, it 
pulls the whole cell body forward by contractile forces generated at the cell body and the rear. 
 
1.2.3 Myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) 
Myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK), is one of the 
downstream effectors of Cdc42. MRCK together with p21-activated kinases (PAKs) was 
identified in our laboratory from a binding assay searching for potential targets of the p21 
Rho family (51). Two isoforms of MRCKs, MRCKα and MRCKβ, were identified while the 
other isoform, MRCKγ, was depicted by Jobert G. et al. (41) and Pirone D.M. et al. (70). The 
significant functions, properties and protein signaling mechanisms of MRCKα, but not 
MRCKβ, have been studied more intensively by our research group for the past ten years. 
MRCKα is a relatively large protein with molecular weight of about 180-200 kDa. According 
to the work of isolation and characterization of MRCKs, MRCKs belong to a family of 
serine/threonine kinases highly related to the myotonic dystrophy protein kinase (DMPK) (11, 
29) and Rho-associated kinases (ROKs/ROCKs/Rho-kinases) in terms of protein sequences 
similarity and their downstream phorsphorylation targets (39, 52, 56). 
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Multiple functional domains were discovered and characterized from MRCKs. All the 
isoforms of MRCKs, including MRCKα, MRCKβ and MRCKγ, contain a highly conserved 
N-terminal serine/threonine kinase domain. An extended coiled-coil domain (CC), a kinase 
inhibitory motif (KIM), a cysteine-rich domain (CRD) that binds phorbol ester, a pleckstrin 
homology domain (PH), a citron homology domain (CNH) and the Cdc42/Rac interactive 
binding (CRIB) domain, are the following functional domains located in order after the kinase 










Fig. 1.10 Functional domains of MRCKα. Kinase domain of MRCKα is flanked by an 
N-terminal sequence and a coiled-coil domain. Cysteine-rich domain (CRD) with kinase 
inhibitory motif (KIM), pleckstrin homology domain (PH), citron homology domain 
(CNH), and Cdc-42/Rac-interactive binding (CRIB) domain are the various functional 
domains presenting between the kinase domain and the C termini.     
 
In fact, much work was focused on the functional and characteristic studies of 
MRCKα. MRCKα, as suggested by its name, was discovered to be the effector of Cdc42 and 
Rac acting downstream of these Rho GTPase. According to an in vitro binding assay, however, 
MRCKα was found to be capable of binding strongly to Cdc42-GTP than to Rac1-GTP. 
Moreover, MRCKα, acting as the effector of Cdc42, has the function in promoting 
cystoskeletal reorganization (51). There are evidences showing that MRCKα has implication 
in Cdc42-mediated peripheral actin formation and neurite outgrowth in HeLa and PC12 cells 
respectively (16). The mechanism where MRCKα regulates actin cytoskeletal reorganization 
is via phosphorylation of a myosin-binding subunit (MBS) of myosin phosphatase 1 (MYPT1) 
(86) and myosin light chain 2(MLC2) (101). Recently, our laboratory discovered that 
MRCKα, by forming a tripartite complex with LRAP3a (Leucine repeat adaptor protein) and 
myosin 18a, is also involved in modulating lamellar actomyosin retrograde flow which is 
crucial to cell protrusion and migration (88). 
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 1.2.3.1 MRCK-related kinases 
MRCKs belong to a large subclass of protein kinases termed the AGC kinases, which 
denote protein kinase A, G and C and other kinases, like protein kinase B/Akt, p70 and 90 
ribosomal S6 kinases, phosphoinositide-dependent kinase-1, ROK, DMPK, and Citron Rho-
interacting kinase (CRIK) (Fig. 1.11). Phosphorylation is vital in the activation of all the AGC 
kinases, though additional regulatory mechanisms are involved for each kinase.  
According to sequence homology and the AGC kinases tree, MRCKs are most closely 
related to DMPK, ROK and CRIK. Their N-terminal kinase domains are very homologous in 
terms of amino acid sequences, for example, the kinase domain of MRCK is about 78.3% 
similar to DMPK. They all have a CC domain following the highly conserved kinase domains 
(87). Furthermore, they also have similar domain arrangement, even sharing similar 
downstream phosphorylation substrate.  Fig. 1.12 shows the alignment of the MRCK kinase 
domain with DMPK, ROK, CRIK, and other related kinases (MLCK, PAK, PKA and PKC). 
MRCK, ROK and DMPK can phosphorylate the MYPT1 of the myosin light chain 
phosphatase (65, 86), while MRCK, ROK and CRIK can phosphorylate the myosin light 
chain (MLC) of myosin II. Myosin II plays a critical role in regulating actomyosin 
cytoskeleton in cell spreading and migration. The activities of myosin II are highly mediated 
by phosphorylation of its regulatory light chain (RLC). Monophosphorylation of RLC at 
Ser19 increases the actin-activated Mg2+-ATPase activity while diphosphorylation at both 
Thr18 and Ser19 further increases the actin-activated Mg2+-ATPase activity (36). In terms of 
MLC2 phosphorylation, Ser19 is the common phosphorylation site for MRCK (88) but CRIK 
and ROK can phosphorylate both Thr18 and Ser19 of MLC2 (103). 
Although the kinase domains of MRCK, DMPK, ROK and CRIK are highly 
homologous, each of them plays different roles in the cells with quite distinct in vivo 
functions. As mentioned earlier, the main function of MRCK is related to the regulation of 
actin cytoskeleton organization. ROK, unlike MRCK, interacts with Rho-GTP but not Cdc42-
GTP and Rac1-GTP. As the effector of Rho, ROK promotes formation of stress fibers and 
18 
 
focal adhesion complexes (52) via MLC2 phosphorylation to enhance actomyosin contraction 
(48) and intermediate filaments (IFs) organization (80). DMPK was reported to have 
functional implication in the generation and maintenance of the skeletal muscle, cardiac 
muscle atrioventricular conduction, cellular ion homeostasis regulation and glucose 



















Fig. 1.11 AGC kinases tree. Red square marks out the most closely related kinases of 
MRCK, which are Rho-associated kinase (ROK/ROCK/Rho-kinase), myotonic dystrophy 















































 Fig. 1.12 The amino acid sequences alignment of the kinase domain of MRCK and 
other kinases. Kinase domain sequences alighment of MRCK with ROK, DMPK, CRIK, 
MLCK (myosin light chain kinse), PAK and PKA (protein kinse A). Areas of amino acid 







1.2.4 Effects and methods of MRCK inhibition 
According to the previous effort carried out by our laboratory, the kinase domain of 
MRCK is negatively regulated by the KIM domain located within the distal CC domain (87). 
This means that the interaction between the KIM domain and the kinase domain results in the 
inactivation of MRCK catalytic activity. A loss of the actomyosin networks in the lamellar 
and subnuclear region was reported in active MRCK-depleted cells (88). Consequently, cell 
migration was impaired due to the disruption of actomyosin retrograde flow (31).  Biological 
molecules or chemical compounds which can inhibit MRCK activity will thus potentially be 
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useful in controlling cell motility. For example, MRCK inhibitor might be applied to stop 
metastasis of cancerous cells.   
There are basically two commonly available methods being used to reduce or 
downregulate MRCK in vivo catalytic activity in. The first method is the use of siRNA, which 
is specific for MRCK, to knockdown the expression of endogenous MRCK and thus lead to 
depletion of the active MRCK. Secondly, introduction of the kinase-dead mutant of MRCK, 
either through transfection or microinjection, into the cells can also bring the same effect as 
decreasing MRCK activity. However, transfection technique is required for the introduction of 
siRNA or kinase-dead MRCK into the cells while highly microinjection has the problem of 
being laborious and low efficiency. Therefore, there is still a lack of a more convenient and 
immediate way to achieve the immediate effect of MRCK inhibition. One of the most ideal 
ways to perturb or to knockout the functions of MRCK would thus rely on the use of a 
chemical drug that can specifically inhibit MRCK enzymatic activity.  
 
1.2.4.1 ROK inhibitors 
Unlike MRCK, six ROK inhibitors are available in the market and many more ROK 
inhibitors have been published in the literature. The most popular and generally used inhibitor 
of ROK is Y-27632. It was discovered and described by Narumiya’s research group in 1997. 
They identified that Y-27632, a pyridine derivative, can target to ROK and can consistently 
suppress ROK-mediated formation and contraction of stress fibers in cultured cells. They also 
found that the compound is able to reduce dramatically high blood pressure in several 
hypertension rat models (94). The working principle of Y-27632 is predicted by targeting and 
blocking ROK from phosphorylating smooth muscle MYPT and MLC2 (43). A decrease of 
myosin phosphorylation subsequently leads to arterial smooth muscle relaxation and 
vasodilation of blood vessels. Other than this, it was also reported to inhibit RhoA-mediated 
cell transformation (77), tumour-cell invasion (40) and neutrophil chemotaxis (66). Therefore, 
from the effects of ROK inhibition, ROK inhibitors are indeed highly potential for anti-cancer 
or anti-inflammatory treatment. 
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HA1077, also known as fasudil hydrochloride, is another compound reported to have 
inhibition effect on ROK (3). This compound has been shown to act as a drug for cerebral 
vasospasm treatment by increasing cerebral blood flow and inhibiting inflammatory response 
(84). Rockout, 3-(4-Pyridyl)-1H-indole, is a selective and ATP-competitor inhibitor of ROK 
activity. It was discovered through an image-based, high-throughput screen of cell monolayer 
wound healing (105). N-(4-Pyridyl)-N′-(2,4,6-trichlorophenyl)urea is also another ATP-
competitive inhibitor of ROK. It was designed via docking simulation of a number or 
compounds on the target protein (85). H-1152 was designed as a more specific, stronger and 
membrane-permeable inhibitor of ROK with a dissociation constant of 1.6nM (38). Lastly, N-
(4-(1H-pyrazol-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide is a ROKII 
inhibitor reported to have high potency in both biochemical and cell-based assays with IC50 in 
nM range. It was also revealed to be highly selective to ROK against other related kinses (27).  
In conclusion, a few chemical compounds that can effectively inhibit ROK activity have been 
identified but inhibitors for MRCK remain yet to be discovered.  
 
1.2.5 Aims of research 
As mentioned above, a few chemical compounds available in the market can act as 
ROK inhibitors. These drugs are useful in assisting the studies of cell migration involving 
ROK pathways. In fact, they can be further tested on clinical trials for therapeutic purposes, 
such as anti-cancer or anti-inflammatory treatment. In contrast, the inhibitor for MRCK, also 
as one of the main components mediating cell migration, is not available. It is therefore of our 
interest to screen and find out the chemical compound(s) that can inhibit MRCK specifically 
in vitro and in vivo. The main objective of this study is first to look for MRCK inhibitor and 




Chapter 2 Materials and methods 
Section 1 
2.1 Protein methodology 
2.1.1 Transformation and protein expression in competent cells 
DNA plasmid, pQE60 MRCKα CAT, pGEX PAK 404 or pQE30 Cdc42wt which had 
been prepared in the laboratory from previous work, was used for transformation. The DNA 
plasmid, with the amount of 5-50 ng, was mixed with 50 μl of E. coli competent cells and was 
incubated on ice for 20 min. The cells were treated with heat-shock for 45 s at 42oC and were 
then chilled on ice for 1-2 min. The heat-shock treated cells were recovered in 100-200 μl 
Luria-Bertani (LB) broth without ampicillin and were shaken for at least 30 min at 37oC. 
Subsequently, the recombinant competent cells were cultivated overnight in 100-200 ml LB 
culture containing 50 μg/ml ampicillin at optimized temperature. The strain of E. coli 
competent cells used for protein expression and the different conditions for growing the 
transformed cells are listed in the table below. 
 
Fusion protein E. coli strain Growing temperature LB culture 
6His-MRCKα CAT XL-1 blue 37oC LB with ampicillin 
GST-PAK 404 BL 21 codon plus 30
oC LB supplement with 20 mM glucose and ampicillin 
6His-Cdc42wt XL-1 blue 37oC LB with ampicillin 
Table 1. E. coli strain and conditions for protein expression 
 
On the next day, the bacterial culture was diluted about 20 folds in LB with ampicillin 
and grown to achieve OD600 of 0.7-0.8. Induction with 0.5 mM IPTG (Invitrogen) for protein 
expression was done by shaking the cells at room temperature for 3-4 hr. Lastly, the cells 
were harvested by centrifugation at 5000-7000 rpm for 10-15 min and ready for fusion 






2.1.2 Protein purification and ion-exchange 
Hexahistadine(6His)-tagged MRCKα CAT or Cdc42wt was purified in 6His-tag lysis 
buffer (50 mM Hepes pH 8, 300 mM NaCl, 25 mM Im, and 0.1% Triton X-100) while GST-
PAK 404 was purified in GST lysis buffer (50 mM Hepes pH8, 150 mM NaCl, 0.5 mM 
MgCl2 and 0.1% Triton X-100). The pelleted cells were first resuspended in respective lysis 
buffer. With the addition of 1 mg/ml Lysozyme, 5 mM DTT (not for 6His-tagged protein), 2 
µg/ml peptide inhibitor Leupeptin and 0.5mM protease inhibitors PMSF in lysis buffer, the 
cells were incubated on ice for 20 min and subjected sonication at 4oC using the Microson 
ultrasonic cell disruptor. Sonication programme was set as 3 × 20 s sonication with 10 s 
interval in between. The crude lysate was then spun by ultracentrifugation using Beckman 
Ti50.2 rotor at 35,000 rpm for 35 min at 4oC. The supernatant was subsequently collected into 
a new falcon tube and 400 μl of either Nikel beads (Qiagen) or glutathione sepharose beads 
(Genscript) was added to fish out 6His- or GST-tagged protein. After 2-3 hr rolling at 4oC, the 
bound protein was collected in a column. The collected beads were washed with 5 × 10 ml of 
lysis buffer and eluted as shown in the following table. 
 
Protein Elution buffer Elution fraction(s) and volume 
6His-MRCKα 
CAT 6His lysis buffer with 250 mM Im 1 × 150 μl , 3 × 300 μl 
GST-PAK 404 GST lysis buffer with 5 mM glutathione 4 × 500 μl 
6His-Cdc42wt 6His lysis buffer with 100, 200, 300 and 400 mM Im (stepwise elution) 4 × 300 μl 




In some cases, thrombin cleavage was performed to remove GST tag. Briefly, 
glutathione beads were resuspended in 500 μl of GST buffer containing 10U/ml thrombin and 
incubated at 37oC for 1 hr. Benzamidine beads (Amersham Biosciences) were then added to 
remove thrombin and rolled at 4oC for about 30 min. The cleaved proteins were eventually 
collected in the flow through fraction.  
Protein concentration of all the eluents was determined by spectrometer measurement 
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using Bradford assay. Overnight dialysis was required for 6His-tagged protein to remove 
Imidazole (Im) from the buffer. Lastly, 5% glycerol was added before aliquoting to smaller 
volume and snap-frozen in liquid nigrogen for storage at -80oC. 
In order to achieve high protein purity for capillary electrophoresis experiment, protein 
was further purified in anion-exchange column using SMARTTM system (Pharmacia Biotech) 
or HPLC. As such, pure protein fraction was then ready for aptamers screening.  
 
2.1.3 Cdc42 GTP exchange reaction and PAK activation 
GTP was used to generate active Ccd42-GTP in solution. GTP exchange reaction of 
Cdc42 was performed in 2 × exchange buffer (25 mM EDTA, 25 mM DTT, 1 M NaCl and 0.5 
M MES-NaOH, pH6.5) with the addition of 2 mM GTP and incubated at 30oC for 10 min. 
The exchange reaction was terminated via addition of 0.05 M MgCl2. Cdc42-GTP was 
required for PAK activation reaction. 
Glutathione bound GST-PAK 404 was resuspended in 300-500 μl lysis buffer after 5 
extensive washes. The beads were spun down in cold at 1,000 rpm for 2 min. Extra buffer was 
removed and the beads were added into kinase buffer (25 mM Hepes, pH 7.3, 25 mM NaCl, 5 
mM β-glycerolphosphate, 2.5 mM NaF, 0.025% Triton X -100, 5 mM MgCl2) containing 2 
mM ATP and Cdc42-GTP. The molar ratio of Cdc42-GTP: GST-PAK 404= 3:1 was used for 
PAK activation. The reaction was carried out at 37oC for 45-35 min. Glutathione bound active 
GST-PAK 404 was collected in a column and washed to removed Cdc42-GTP and excess ATP, 
and was finally eluted with glutathione. 
 
2.1.4 Testing kinase activity of MRCKα 
Either radioactive method or non-radioactive method of kinase assay was carried out to 
test the kinase activity of MRCKα. For radioactive method, MRCKα was incubated with 5 µg 
GST-MLC2 (myosin light chain 2) as substrate and 10 μM ATP with 0.2 μl [γ-32P]ATP (3,000 
Ci/mmol; NEN) in kinase buffer at 30oC for 15-20 min. For non-radioactive method, it was 
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done similarly without [γ-32P]ATP and the phosphorylation of substrate was detected in 
Western blot using anti-pS19 MLC2 (Cell Signaling Technology) at 1:2000 dilution. 
 
2.1.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide gels were used for proteins analysis and separation. Bio-Rad Mini-
PROTEAN gel casting system was used to cast gels with desired percentage of acrylamide 
concentration. The recipe of a typical 10% gel is shown as below: 
 
Ingredients Resolving gel Stacking gel 
H2O 2.395 ml 1.05 ml 
1.5M Tris-HCl pH8.8 2.5 ml - 
0.5M Tris-HCl pH6.8 - 0.625 ml 
10%SDS 100 μl 25 μl 
50% glycerol 1.616 ml 0.4 ml 
30% Acylamide/Bisacrylamide (29:1) 3.25 ml 0.4 ml 
10% ammonium persulphate (APS) 62.5 μl 12.5 μl 
N,N,N,N,-Tetramethyl-Ethylenediamine 
(TEMED) 6.25 μl 5 μl 
Table 3. The recipe of a typical 10% polyacylamide gel. 
 
Protein samples were mixed with 2 × sample buffer (50 mM Tris-HCl pH6.8, 6% SDS, 
2% β-mercaptoethanol, 0.1% bromophemol blue and 50% glycerol) and were boiled for 5-7 
min prior to loading. Gel electrophoresis was carried out in running buffer containing 25 mM 
Tris-HCl pH 8.0, 192 mM glycine and 0.1% SDS at a constant voltage of 150-180V for 1-1.5 
hr.  
 
2.1.6 Coomassie blue staining 
For protein analysis with Coomassie Blue staining, gels were soaked in staining solution 
containing 1% (w/v) Coomassie brilliant blue, 40% (v/v) methanol and 10% (v/v) acetic acid 
for more than 1 hr or overnight. The gels were subsequently destained in destaining solution 




2.1.7 Western blot 
For protein detection using Western blotting, proteins were first transferred to 
polyvinylidene difluoride (PVDF) membranes using Bio-Rad semi-dry transfer apparatus. 
After that, the PVDF membrane was blocked in PBS containing 5% skimmed milk and 0.1% 
Tween for at least 30 min. The membrane was then washed with PBS containing 0.1% Tween 
and was probed with specific primary antibody in PBS 0.1% Tween for 2 hr with rolling at 
room temperature (RT) or overnight at 4oC. The membrane was washed extensively to 
remove unbound primary antibody before probing with horseradish peroxidase (HRP)-
conjubated anti-mouse or anti-rabbit IgG (Dako) at RT for 1 hr. The membrane was again 
washed extensively prior to visualization of protein bands by enhanced chemiluminescence 
(ECL) reactions and exposed onto X-ray films, which were developed by a Kodak X-ray film 
processor. 
 
2.2 Aptamer selection methodology 
2.2.1 Single-stranded DNA (ssDNA) and MRCKα incubation 
A FAM-tagged ssDNA library consisting of 40-base random sequences flanked by 20-
base constant sequences at two sites: 5’-/6-FAM/ AGCAGCACAGAGGTCAGATG (40N) 
TTCAGCGTAGCACGCATAGG-3’, was purchased from Integrated DNA Technology, Inc.  
A 100 μM concentration of ssDNA library was dissolved in Tris-EDTA (TE) buffer (10mM 
Tris, pH7.5, 1mM EDTA) and was kept as stock in cold. Prior to CE selection, 50 μM of 
ssDNA library, diluted in MRCKα binding buffer (50 mM Tris, pH 8.3, 50 mM NaCl and 
5mM MgCl2), was first denatured at 95oC for 10 min and then cooled down to 20oC at a rate 
of 0.5oC/s. Final concentration of 25 μM ssDNA library was incubated with 500 nM or 10 μM 






2.2.2 Capillary electrophoresis 
Before selection of aptamers for MRCKα, the elution time of ssDNA library and 
MRCKα migration pattern was tested on a few different running buffers containing Tris-
borate, Tris-HCl (Promega), sodium borate (Merck) or sodium phosphate, in which 
concentration ranged from 20 to 100 mM and pH ranged from 7 to 9. These buffers were used 
as their buffering capacity and their properties would not be too harsh to MRKC kinase 
domain (pI value is 5.08). The type of capillary used for CE run was also optimized and a 60 
cm long (50 cm to detector) fused-silica capillary purchased from Polymicro Techonologies 
(Phoenix, USA) with an inner diameter of 50 µm and outer diameter of 360 µm was chosen. 
The elution time of ssDNA library or MRCKα was detected at wavelength 260 nm or 200/280 
nm respectively. The real elution time of ssDNA or MRCKα to the end of capillary was 
obtained by multiplying the elution time, taken from the electropherogram, with 1.2 (ƒ = 
Ltotal/Ldetector). The elution time of MRCKα was further confirmed by doing collecting fraction 
at 1 min interval over 5 min where the peak of MRCKα was detected for 10 times. The 
collected fractions were run on a 10% polyacrylamide gel and Western blot was done to 
visualize the intensity of the protein bands. With the optimized running buffer, the aptamers 




Non-SELEX was used as the separation method for aptamer selection by using a P/ACE 
MDQ apparatus (Beckman Coulter, Mississauga, ON, Canada) equipped with Photodiode 
array detector. Both the inlet and the outlet reservoirs of the capillary were supplied with CE 
running buffer. The capillary was rinsed with 0.1 M HCl (Fisher Scientific), 0.1 M NaOH 
(Fluka), deionized H2O and followed by the CE running buffer for 2 min each between each 
run. After rinsing, ssDNA aptamers and MRCKα incubation sample were then injected into 
the capillary by a pressure pulse of 5 psi × 15 s or 5 psi × 10 s. The partition was performed 
under the following conditions: 20 kV, 333 V/cm, 20oC and normal polarity (cathode at outlet 
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end). Approximately 1012 sequences were injected into the capillary for the first selection. 
The MRCKα bound ssDNA fractions were collected in an automated mode by replacing the 
regular outlet reservoir with a collection vial containing 5 µl of 500nM MRCKα in binding 
buffer. The collected fractions were subjected to the next round of separation. A few rounds 
of selection were carried out until an enriched pool of aptamers with reasonably high affinity 
to MRCKα was obtained. At the end of every run, the capillaries were rinsed as described 
previously excluding the CE running buffer. 
 
2.2.4 Enriched aptamer pools, clusters and single clones binding analysis 
The binding affinities of collected fractions amplified by polymerase chain reaction 
(PCR), of ssDNA aligned clusters and of ssDNA single clones were analyzed by CE-P2 
machine equipped with light-induced fluorescence (LIF) detector at Department of Chemistry, 
NUS. In most cases unless otherwise stated, 100nM of the corresponding ssDNA samples 
were denatured by heat as done previously and incubated with 1 µM MRCKα for 15 min or 
overnight. The ssDNA and MRCKα mixture was injected into the capillary at a pressure of 1 
psi × 10 s. The dissociation constant (Kd) of the corresponding ssDNA samples towards 
MRCKα was calculated using the formula as shown below. The free ssDNA peak area, 
ssDNA-MRCKα complex peak areas and the complex dissociating area were integrated from 
the electropherograms using the software Clarity 5.5.0.  
 
 
Here [T]0 and [DNA]0 are the total concentrations of the target and DNA respectively. ADNA is 
the area of the peak of free DNA divided by the migration time of free DNA, ADNA·T is the 
area of the peak of DNA that dissociated from the complex during NECEEM divided by the 
migration time of free DNA and Adiss is the area of the peak of the intact complex that reached 





2.3 DNA methodology 
2.3.1 Enriched aptamer pools amplification 
The collected fractions of aptamers were amplified via PCR. Vent taq polymerase (New 
England Biolabs; 0.06 U/μl), collected aptamers as templates, a FAM-tagged forward primer 
(5’/-FAM6/AGC AGC ACA GAG GTC AGA TG; 1.5 μM), a biotinylated reverse primer 
(5’/biotin/-TTC ACG GTA GCA CGC ATA GC-3’; 1,5 μM), MgCl2 (4 mM) and dNTPs (250 
μM each, New England Biolabs, Inc.) were used for PCR amplification. The PCR mixed 
sample was first denatured at 94oC for 5 min. Subsequently, a total of 23 cycles of 
denaturation (30 s, 94oC), annealing (30 s, 53oC), and extension (20 s, 72oC) were performed 
and the reaction was terminated after a final extension for 5 min at 72oC. The PCR product 
was analyzed on a 2 % agarose gel containing 0.5 mg/ml ethidium bromide. DNA samples 
were mixed with 5 × sample buffer (10 mM Tris-HCl (pH 7.6), 0.03 % (w/v) bromophenol 
blue, 0.03 % (w/v) xylene cyanol, 60 % (v/v) glycerol, and 60 mM EDTA) before loading 
onto the gels. TAE buffer (0.04 M Tris-acetate, 0.01 M EDTA) was used as the running buffer 
and a complete DNA agarose gel electrophoresis on a 2% agarose gel was done at a constant 
voltage of 120 V for 30 min. The DNA bands were visualized with ethidium bromide stained 
by using UV illumination.  
 
2.3.2 ssDNA aptamers pufication 
The amplified double-stranded DNA (dsDNA) product was purified into ssDNA by 
passing through a streptavidin-agarose (Upstate, USA) column. The streptavidin agarose 
beads were first packed in a 1 ml blue tip and equilibrated with streptavidin binding buffer (10 
mM Tris, pH 7.5, 50 mM NaCl, and 1 mM EDTA). The PCR product was diluted half with 
the streptavidin binding buffer and passed through the equilibrated streptavidin-agarose 
column. After the whole sample has passed through the column, it was washed with 1 ml of 
streptavidin buffer for 5 times. dsDNA with a biotinylated complementary strand would bind 
streptavidin to the column and remain in the column. Finally, the wanted desired ssDNA 
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aptamers were eluted with 400 μl of 0.15 M NaOH at 37oC. 60 μl of 1 M HCl was added into 
the eluted fraction to bring the pH down to neutral. Ethanol precipitation was done to 
concentrate the eluted ssDNA and this formed the enriched pool of ssDNA aptamers.    
 
2.3.3 Cloning and sequencing of enriched aptamer pools 
After 4 rounds of selection, the enriched pools with improved binding affinity were 
cloned and sequenced. The enriched pools were re-amplified with primers that contained 
BamHI and SalI restriction sites added to the 5’ end with no FAM or biotin tag. High fidelity 
PCR using taq DNA polymerase (NEB) was performed to amplify the enriched pool for 
cloning. The PCR conditions were similar to the PCR conditions described above, except only 
12 cycles and a final extension of 10 min at 72oC were carried out.  
After PCR, the dsDNA product was cleaned up by a miniprep column to separate desired 
dsDNA product from primers and dNTPs. An aliquot of the dsDNA with restriction enzyme 
cut sites and 1 μg of pGEX 4T-1 plasmid vector were digested with BamHI and SalI 
restriction enzymes for 1-2 hr. The digested DNA and vector were then separated by 
electrophoresis on a 2 % low-melting point (LMP) agarose gel. The electrophoresis procedure 
was done as described above. The DNA and vector bands were excited out from LMP gel 
according to their base pair size. The cut DNA fragments were subsequently cloned into the 
plasmid vector by doing in-gel ligation. The excised DNA fragments and vector bands were 
washed with H2O and were melted in 150-200 μl of H2O respectively at 70oC for 5 min. 
Ligation mixture containing 3 μl of plasmid vector, 12 μl of DNA fragment, T4 ligase in 
ligation buffer was prepared. In-gel ligation reactions were performed for more than 1 hr or 
overnight at RT or 16oC respectively.  
After ligation, the ligase was inactivated by heat at 70oC for 5 min. The ligated constructs 
were transformed into XL-1 Blue E. coli bacteria. Colonies were picked as many as possible 




2.3.4 Sequences alignment 
DNA aptamer sequences that were collected from the sequencing results were aligned 
together by using clustalW program from the website 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). A phylogenetic tree was generated and 
clusters were determined. DNA sequences in the same clusters were re-aligned to identify 
consensus regions.  
 
2.3.5 Clusters and single clone amplification 
Aptamer sequences, which were previously cloned into pGEX 4T-1 plasmid vector, were 
cut out from the construct with BamHI and SalI restriction enzymes. The enzymatic digested 
DNA fracgment was purified on a 2% LMP agarose gel. The excised DNA fragment was 
melted in 200 μl of water and was then used as template in asymmetric PCR reaction. For one 
reaction of asymmetric PCR mixture, it contained 1 μM of FAM-tagged forward primer (5’/-
FAM6/AGC AGC ACA GAG GTC AGA TG; 1.5 μM) with less reverse primer (5’-TTC ACG 
GTA GCA CGC ATA GC-3’), which was 1 nM, 250 μM of each dNTPs, 0.05 U of Hot Star 
Taq polymerase, and 10 μl of DNA template in a total volume of 100 μl. Initial denaturation 
was done at 95oC for 15 min, followed by 40 cycles of denaturation at 94oC for 30 sec, 
annealing at 58oC for 1 min, and extension at 72oC for 30 sec. The PCR reaction was 
completed with a final extension at 72oC for 5 min.  
 
2.3.6 Aptamer-MRCKα in vitro pull-down assay 
Aptamers-MRCKα pull-down assay was done as an alternative method to confirm the 
binding of the aptamer to MRCKα. Biotinylated ssDNA aptamer (aitbiotech; 0.4 µM), 
MRCKα-CAT (2 µM), poly-dIdC (0.09-0.08 µg/µl), with total volume of 200 µl, were 
incubated in MRCKα binding buffer at 4oC for 2 hr. Prior to incubation, all ssDNA aptamers 
were heat denatured first as described above. Streptavidin beads (30 µl /reaction) were pre-
blocked in 1 % BSA and equilibrated with MRCKα binding buffer. 30 µl beads were then 
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packed into a yellow tip and used as a column for aptamer-MRCKα pull-down assay. The 
incubated mixtures were passed through the streptavidin column 2 times to pull down biotin-
tagged aptamers. After that, 5-6 washes with 200 µl binding buffer were carried out to wash 
away unspecific binding. The aptamer-bound MRCKα was then eluted with 30 µl of 2 X 
sample buffer by boiling at 100oC for 7 min. For analysis, SDS-PAGE using 10 % gel was run 
and western blot using anti-6Histidines antibody (1:1000; Sigma) was performed to detect the 
binding of MRCKα to the biotinylated aptamer.   
 
Section 2 
2.4 MRCKα inhibitors screening 
The screening was done with the help from ETC (Experimental Therapeutics Center) 
group by using an automatic robot at Nanos, Biopolis. Chemical compounds were screen in 
duplicates in a 384-well plate to identify MRCKα kinase inhibitor. Firstly, 2 µl of 20% 
DMSO, as control, or compound was added into each well. The final concentration of 
compound used for screening is 1 µM. Purified recombinant 6His-MRCKα CAT (2.72 ng) 
was added into all wells subsequently. Substrates mixture including 3.15 µg of purified GST-
PIM (phosphatase inhibitory motif) and 5 µM of ATP was subsequently added into the 
mixture of compound/solvent and MRCKα CAT. The total volume of the whole incubation 
mixture in a well was 20 µl. The in vitro kinase reaction was done at RT for 20 min or 1 hr. 
After 20 min or 1 hr incubation, equal volume (20 µl) of Kinase-Glo Reagent (Promega) was 
added into each well to stop the kinase reaction. The Kinase-Glo Reagent contains flyer fly 
luciferase which will convert ATP into light signal. Ten-minute incubation was required 
before proceeding to luminescent signal measurement with Safire II, Tecan.  
 
2.5 Protein methodology 
2.5.1 Preparation and cloning for constructs of MRCKα-CAT and other kinases 
DNA constructs of ROKα-CAT1-543, CRIK-CAT1-520, DMPK-CAT1-466, MLCK-CAT1424-1740, 
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and PKCα-CAT308-673 were prepared and cloned into either pQE30 bacterial vector or pxj-
6His-biotin mammalian vector. Constructs of MRCKα-CAT1-473, PAK full length and PKA 
full length were already prepared and available for used. Detailed information with respect to 
the types of cloned vector and cloning sites for each DNA constructs is presented in Table 4. 
 
Cloning sites Gene Cloned vector Start site End site 
ROKα-CAT1-543 pxj-6His-biotin BamH I Not I 
CRIK-CAT1-520 pQE30 Xho I Pst I 
DMPK-CAT1-466 pQE30 BamH I Sac I 
MLCK-CAT1424-1740 pxj-6His-biotin BamH I Pst I 
PKCα-CAT308-673 pxj-6His-biotin BamH I Sph I 
        
Table 4. Types of cloned vector and cloning sites for constructs of catalytic domain of 
some kinases in this study. 
 
2.5.2 Protein expression and purification of MRCKα, PIM, MLC2 and other kinases 
Hexahistidine-MRCKα CAT, GST-PIM (phosphatase inhibitory motif) MYPT (myosin 
light chain phosphatase) and GST-MLC2 were purified as mentioned in 2.1.2. Radioactive 
kinase assay was also done to confirm that GST-PIM and GST-MLC2 can be phosphorylated 
by 6His-MRCKα CAT.  
Kinase catalytic domains of ROKα, CRIK, DMPK, MLCK and PKCα were expressed 
and purified while GST-PAK 404 was prepared as aforementioned and 6His-PKA was already 
available in our laboratory. CRIK and DMPK were tagged with 6 Histidines and were 
expressed and purified from E. coli XL-1 Blue. The purification method was same as 6His-
MRCKα CAT as mentioned previously. Mammalian constructs of ROKα, MLCK and PKCα 
were transfected into 60-70% confluent COS7 cell line. The transfected cells were harvested 
on the next day in lysis buffer (25 mM Hepes, pH7.3, 1.5 mM MgCl2, 0.2 mM EDTA, 5% 
glycerol, 1 mM sodium orthovanadate, 20 mM β-glycerol phosphate) with 0.5% Triton-X 100, 
300 mM NaCl, 25 mM Im and proteases inhibitors cocktail. After homogenization of the 
harvested cells, the membrane fractions and cell debris were spun down at 4oC at 13,000 r.p.m. 
The supernatant was transferred into a new tube and 30 µl of Nikel beads were added into the 
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supernatant. Hexahistidine-tagged kinases were pulled down by rolling the tubes in the cold 
for 2-3 hrs. After that, the beads were spun down in cold at 1,000 r.p.m. Subsequently, the 
beads were washed 4 times with 500 µl of washing buffer (same as lysis buffer but with 
0.25% Triton-X 100) in a column. Low salt washing buffer (50mM NaCl) was used for the 
last wash. The kinases were eventually eluted in elution buffer (same as lysis buffer but with 
50mM NaCl, 300mM Im and 0.25% Triton-X 100). Purified kinases were run on 12-10% of 
polyacrylamide gels for analysis. Eventually, the activity of the purified kinases was tested by 
doing radioactive kinase assay as describe in 2.1.5. 
 
2.5.3 Studies of substrate specificity for MRCKα-related kinases  
Kinase assay was carried out in a total of 30 μl of reaction mixture containing about 40 
ng of kinases, 5 μg of substrate (GST-PIM or GST-MLC2) and 10 μM ATP in kinase buffer. 
ATP supplement with 0.1 µl [γ-32P]ATP was used in kinase reaction containing GST-PIM as 
substrate. The kinase reaction was done at RT for 20 min. The phosphorylation state of the 
substrate was analyzed by 12% SDS-PAGE and Western blot using anti-pS19 MLC2 (1:2000) 
or anti-ppT18/S19 MLC2 (1:2000; Cell Signaling Technology) as primary antibodies in 
kinase reaction when GST-MLC2 was used as substrate.  
 
2.6 MRCKα inhibitors characterization 
2.6.1 Selectivity studies of inhibitors  
The inhibition effects of 5 μM or 10 μM of Chelerythrine chloride (LC lab) was tested 
on 40 ng of MRCKα, DMPK, CRIK, MLCK, PAK, PKA and 10ng of ROKα . MRCKα and 
ROKα were also tested with 5 μM of Y-27632 (Calbiochem), 10nM or 50nM of Staurosporine 
(Sigma), 10 μM of ML-7 (Calbiochem), and 1 μM of H89 (LC lab) for inhibitors selectivity 
studies. Concurrently, MLCK, PKA and PKCα were incubated with their respective known 
inhibitors as controls. Kinase assay was carried out by incubating the kinases with the 
chemical inhibitors for 5 min prior to the addition of 5 μg substrate and 10 μM ATP 
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supplement with 0.1 μl [γ-32P]ATP to initiate the kinase reaction. The effects of the chemical 
inhibitors were analyzed using 12 % SDS-PAGE.   
 
2.6.2 IC50 estimation for inhibitors  
Chelerythrine chloride and Y-27632 (ROKα inhibitor) were diluted serially from the 
range of 0.2 µM to 5µM. A higher range, 2.5 µM to 10 µM, was used for chelerythrine 
chloride selectivity study on ROKα and CRIK. Serial concentrations of the inhibitor were pre-
incubated with 40ng MRCKα, 10ng ROKα  or 40ng CRIK for 5 min. Kinase assays were 
carried out at RT for 20 min by adding in 5 µg of GST-PIM or GST-MLC2 as the substrate, 
100 µM or 10 µM ATP with 0.1 µl [γ-32P]ATP in kinase buffer (as described above). The 
effect of the inhibitors on the kinase activity was confirmed by 12 % SDS-PAGE and the 
remaining kinase activities were quantified by the Molecular Dynamics PhosphorImager 
System (Fuji). In this process, the signal from 32P was exposed shortly (within 30 mins) to the 
PhosphoImager and scanned into computer. Short exposure time was performed due to the 
high level of phosphorylation in this assay. Next, a program, Multi Gauge, was used to 
quantify the signals by comparing them with the background and the control. Subsequently, a 
curve was plotted using the values from the program for IC50 estimation. 
In this study, the radioactive kinase assay was preferred over the conventional filter 
binding assays due to the high background coming from MRCK autophosphorylation. It is a 
reasonable assumption that the resolution of 32P labeled substrate on PAGE gel should allow 
more accurate quantification of substrate phosphorylation. 
 
2.6.3 Drugs treatment in HeLa cells and immunofluorescent staining of cells 
Around 60-70% confluent HeLa cells were cultured onto coverslips. On the next day, 
desired concentrations of the inhibitors (2.5 µM and 5 µM of Chlerythrine chloride, 5 µM 
Sanguinarine, 5 µM of Y-27632, 10 µM of ML-7, 1 µM H89) were treated onto HeLa cells 
for 30 mins or 1 hr. After the incubation period, cells were washed with PBS and fixed in 4% 
paraformaldehyde for 20 min at RT or fixed in cold methanol for 10 min at 4oC, following by 
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washing in PBS and permeabilization with 0.2 % Triton-X100/PBS for 10 min. The 
physiological effects of the inhibitors were confirmed by doing immunofluorescent staining 
using self-raised anti-MRCKα mouse (1:50) and anti-pS19 MLC2 (1:75) or anti-ppT18/S19 
MLC2 (1:75) antibodies as primary antibodies. The primary antibodies diluted in 0.5% 
Triton-X 100/PBS were incubated onto the cells overnight at 4oC. On the next day, the cells 
were washed two times with 0.1% Triton-X 100/PBS and were then incubated with Cy3-
conjugated anti-mouse (Jackson Immmuno Research Laboratory) and Alexa-488 conjugated 
anti-rabbit (Molecular Probes) as secondary antiboies and Alexa-647 phalloidin (1:300; 
Molecular Probes) for 1 hr at RT in the dark. Eventually, two washes were performed and the 
coverslips were mounted onto glass slides for image capture using a Coolshap HQ (Roper 
Scientific) adapted to a Zeiss Axioplan wide-field fluorescent microscope.   
 
2.6.4 Wound healing assay 
U2OS cells were plated onto coverslip at about 90% confluence in Dulbecco’s modified  
Eagle’s medium containing 1% FBS. The confluent cells were scratched with a pipette tip and 
replaced in medium containing either DMSO as control or 2.5 µM Chelerythrine chloride as 
treatment. The process of cell migration was recorded for 4 hrs after recovery. The distance of 





Screening of Aptamers for Myotonic Dystrophy Kinase-Related Cdc42 Binding Kinase 
(MRCK) by CE-SELEX 
 
3.1 Introduction 
SELEX (Systematic evolution of ligands by exponential enrichment) is a method 
commonly used in RNA and DNA aptamer selection for specific targets of interest. Hundreds 
of RNA aptamers specific to small molecule and protein targets have been successfully 
selected through the use of this method. They include from small molecules like ATP and GTP, 
to larger molecules, such as thrombin (33, 102). The widespread success in the selection of 
functional RNAs raised the issue of whether DNA could also give rise to functional sequences. 
In recent years, single-stranded DNA (ssDNA) aptamers against many different targets have 
been selected (102). The conventional SELEX methods, such as affinity column method and 
membrane filtration method, have been used for aptamer selection. This leads to the 
identification of a nucleic acid aptamer against thrombin using affinity column SELEX 
method (10).  
Many improvements have been made on the conventional SELEX method in recent 
years. CE-SELEX, a non-conventional SELEX, is one of the methods reported to be able to 
improve the efficiency of selection by reducing the number of selection cycles and shortening 
the time to isolate high-affinity aptamers (58, 104). By applying CE-SELEX, aptamers 
against many targets, such as IgE (60) and neuropeptide Y (59), have been selected. 
Introduction of non-SELEX selection process further decreases the aptamer selection time as 
repeated partitioning steps are carried out without amplification (6). In this study, we have 
applied this method in a screening of aptamers specific for MRCK kinase domain (refer to 
MRCK in this study) due to the convenience and rapid processing time. Moreover, we also 
design to select aptamers with the ability in discerning conformational differences between 
active and inactive MRCK.  
Though CE in combination with non-SELEX is a relatively new technique for 
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aptamer selection, it has some other inherent problems such as the small volume injection of 
aptamers for partition. Some initial modifications on the original non-SELEX protocol were 
thus implemented to solve this problem and to increase the efficiency of MRCK aptamer 
selection. 
 
3.2 Non-SELEX conditions for MRCK aptamer selection 
Method development of NECEEM-based non-SELEX was performed to determine 
the optimal conditions for aptamer selection. It is crucial to determine a proper aptamer-
collection window for MRCK-aptamer selection as this will affect the selection of aptamers 
with high affinity to the targets. In order to obtain a wider collection window, parameters that 
need to be optimized are the choices of buffer, its concentration and pH of CE running buffer. 
In addition, salt composition of selection buffer, protein concentration and sample injection 
size are also taken into consideration (7). 
The CE running buffer was chosen according to the separation distance of a target 
from DNA. Tris, phosphate and borate buffers are the three buffers which are normally 
employed for the purpose of separating biological analytes (12). Suitable pH within the 
buffering range of the buffer and the buffer concentration need to be considered. A few 
concentrations of Tris, phosphate and borate buffer with pH 7-9 were tested. Fig. 3.1 shows 
the migration pattern of MRCK under phosphate buffer pH 7 and borate buffer pH 9. 
Prior to CE separation, aptamers and target protein are incubated in selection buffer 
which contains NaCl and MgCl2. The components of the selection buffer also require 
optimization. Various concentrations of NaCl in the selection buffer were studied. When 
phosphate buffer was used as CE running buffer, the optimized selection buffer that gave rise 
to observable MRCK-aptamer complex peaks was found to be 50 mM Tris, 50 mM NaCl and 
5 mM MgCl2 (Fig. 3.2) The bulk affinity of naïve DNA library under these conditions was 
calculated to be 150 µM. As 500 nM MRCK concentration was used, the protein peak is too 



































































Fig. 3.1 Optimization of CE running buffer for MRCK aptamer selection. The 
migration pattern of MRCK protein peak in (A) Phosphate buffer pH 7 and (B) borate 
buffer pH 9 at different buffer concentrations. The migration pattern of MRCK 
protein peak was affected by the buffer types, concentration and pH of the CE running 
buffer. Black arrows indicate the protein peak of MRCK under each condition.  
(B) Borate buffer pH 9 
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One of the advantages of using CE is that it requires only a small amount of analytes 
and the sample injection size is in the scale of nanolitres. However, this small injection 
volume disallowed injection of a large number of DNA library sequences in one single round 
of selection. One solution is to use a highly concentrated library to increase the number of 
DNA molecules per injection. However, high DNA concentrations gave rise to broad peaks 
that worsens the separation between free and target-bound DNA, leading to poor partitioning 
efficiency. A library with a concentration of 25 µM of DNA with an injection pressure of 5 psi 
for 15 seconds was used as a compromise between injection size and resolution. This loading 
size contained a total of 2 x 1012 sequences that were screened for binding with MRCK upon 





Fig. 3.2 Electropherograms of DNA library and MRCK. (1) 100 nM FAM-tagged 
naïve DNA library and (2) 17.5 µM MRCK incubated with 100 nM FAM-tagged naïve 
DNA library. 50 mM phosphate buffer pH 7 was used as CE running buffer. Red circle 
indicates the complex peaks. 
[min.]
Time










3.3 Original non-SELEX approach as an initial screening of MRCK aptamers 
In an initial screening of MRCK aptamers, an original non-SELEX approach as 
described by Berezovski M et al. (6) was applied. Phosphate buffer with pH 7 was used in 
this CE protocol. DNA library at 25 μM concentration was incubated with 500 nM of MRCK 
prior to injection. Fig. 3.3 shows the enriched aptamer pools obtained up to three rounds of 
positive selection against MRCK. As more than one complex peak was observed, it suggests 
that MRCK may interact with DNA with several stoichiometries. In order to calculate the 
dissociation constant (Kd) of enriched aptamer pool, peak areas of all complexes were 
integrated and the Kd values were calculated using the formula in Section 2.2.4. Table 4 
summarized the Kd values of these three enriched aptamer pools. The bulk affinity of the best 
enriched aptamer pool obtained was approximately 450 nM after two rounds of positive 
selection. The second and third enriched aptamer pools have almost the same Kd. As a result, 
no significant improvement of Kd was observed from the third round of selection.  
 





Table 4. Dissociation constant (Kd) of the first to third enriched aptamer pool from 


















Fig. 3.3 Electropherograms of enriched aptamer pools from the original non-SELEX 
method. 1 µM of MRCK was incubated with 100 nM of first (A), second (B), and third (C) 
enriched aptamer pools. Aptamers alone without MRCK were run as controls. Other peaks, 
circled in red, which migrated before the free DNA peak were observed to be complex peaks. 
A
Aptamer alone 
1st enriched aptamer pool  
B 2nd enriched aptamer pool  
Aptamer alone 
Aptamer alone 
3rd enriched aptamer pool  C
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3.4 Modified non-SELEX approach for improvement in MRCK aptamer selection 
3.4.1 Confirmation of MRCK and aptamers retention time 
In order to improve the quality of aptamer selection for MRCK, some modifications 
were made on the original non-SELEX protocol. Before applying the new approach of non-
SELEX method, the retention time of MRCK and DNA aptamers in the capillary was checked 
and confirmed respectively. According to Fig 3.4A, MRCK protein peak was confirmed by 
UV detection at wavelengths of 200 nm, 260 nm and 280 nm. When 100 mM borate buffer 
was used as CE running buffer, the migration time of MRCK was predicted to be around 8 
minutes. By running different concentrations of MRCK, the detection limit of CE at 
wavelength of 200 nm was found to be 10 µM of MRCK as showed in Fig 3.4B. Apparently, 
10 µM of MRCK was still able to be detected but not 1 µM MRCK. To further confirm the 
observed peak belongs to MRCK, a mixture of MRCK and aptamers were injected into CE 
and five fractions were collected at every 1 minute interval from 7 to 12 minutes. The five 
collected fractions were analyzed by western blotting (Fig 3.5). The retention time of MRCK 
was confirmed at the regions from 8-9 minutes. As mentioned previously, DNA aptamers are 
more negatively charged than MRCK and thus migrate later than the protein. The retention 
time of DNA aptamer was found to be at approximately 11-12 minutes as shown in the 





















Fig. 3.4 Electropherograms for MRCK protein peak and DNA aptamer peak 
detection. (A) MRCK peak can be detected by UV at wavelengths of 200 nm, 260 nm and 
280 nm. Red arrows point to the protein peak of MRCK. (B) Serials concentrations (126 
µM, 50 µM, 10 µM and 1 µM) of MRCK were run on CE to check the detection limit of 
the UV detector. The detection limit was found to be 10 µM of MRCK. (C) The 
electrophoretic migration profiles of the target protein, MRCK, at a concentration of 77 µM 
MRCK and DNA library at a concentration of 25 µM were aligned side by side. All the 
runs were performed in CE running buffer using borate buffer at pH 9.   
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 Fig. 3.5 Confirmation of MRCK migration time using western blot. Five fractions were 
collected at every 1minute interval from 7-12 minutes. The collected fractions were run on a 
protein gel and subjected to western blot (IB) using anti-6 histidines antibody. MRCK 
standard with the amount of 5 ng, 10 ng, 50 ng and 100 ng was as control and for the 
estimation of protein amount. Sensitive enhanced chemiluminescence (ECL) used in the blot 







3.4.2 MRCK aptamer selection using modified non-SELEX approach 
The main problem of the non-SELEX approach is that the number of DNA aptamer 
molecules which can be injected into the capillary for partition is rather restricted due to the 
small injection volume. In order to solve this problem, an incubation of 25 µM of DNA with 
10 µM of MRCK and 0.09-0.08 µg/µl of poly-dIdC was injected 10 times into the capillary. 
Meanwhile, 10 collections on the aptamer-collection window were also carried out. The 
collection window in the first round of selection was determined to be around the MRCK 
protein peak, which was 7.5-10.5 min as shown in Fig. 3.6. In brief, these collected fractions 
were ethanol precipitated in the presence of poly-dIdC and resuspended in the desired volume 
for the next round of selection. In the subsequent rounds of selection, the selection processes 
were performed using 500 nM of MRCK as target concentration to reduce the unspecific and 
weakly bound aptamers. Simultaneously, the collection window was changed to 6.5-10.5 min 
to avoid missing out of specific binders for MRCK. Ten collections were performed in each 
round of selection and a total of three positive selections against MRCK were implemented. 
These ten collections from each round of selection eventually formed the first to third 
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 Fig. 3.6 Electrophoretic migration profile of MRCK together with DNA library and 
poly-dIdC. In the modified non-SELEX method, 10 µM of MRCK was incubated with 25 
µM of DNA library and poly-dIdC. The mixture was injected into capillary for separation 
after 15 minutes of incubation. Aptamer collection window, as indicated, which is marked, 




Similar to the original non-SELEX protocol, three rounds of selection were also 
performed in this modified non-SELEX method. Fig 3.7 shows the electropherograms of the 
binding analysis of these three enriched aptamer pools. The amplified enriched aptamer pools 
were either incubated with MRCK for 15 minutes or overnight. In the first enriched aptamer 
pool, 15 minutes incubation gave no obvious complex peak and only one complex peak was 
detected in the overnight incubation. One complex peak migrated just before the free DNA 
peak was observed in the second enriched pool and many more complex peaks were found in 
the third enriched pool. The Kd values of each enriched aptamer pool for MRCK were 
calculated and summarized in Table 5. 
 





Table 5. Dissociation constant (Kd) of the first to third enriched aptamer pools from 
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1st enriched aptamer pool 
(1)Aptamers alone 
(2) 15 min 




















2nd enriched aptamer pool 
(1) Aptamers alone 


















2 4 6 8 10 12 14
(1) Aptamers alone 
(2) 15 min 
3rd enriched aptamer pool 
Fig. 3.7 Electropherograms of enriched aptamer pools from the novel non-SELEX 
method. 1 µM of MRCK was incubated with 100 nM of first (A), second (B), and third (C) 
enriched aptamer pools. Aptamers alone without MRCK were run as controls. Other peaks, 
circled in red, which migrated before the free DNA peak are observed to be complex peaks. 
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3.5 Comparison of the original and modified approach non-SELEX protocol 
Two non-SELEX approaches were performed and the enriched aptamer pools from 
each approach were compared in terms of their binding affinities towards MRCK using CE 
and an in vitro MRCK pull-down assay.  
 
3.5.1 Original non-SELEX 
In the original approach, the second enriched aptamer pool was cloned and sequenced 
for further analysis. A total of 46 clones from the aptamer pool were cloned and sequenced to 
obtain the individual DNA sequences. Sequence alignment was done using ClustalW2 
software to generate a phylogenetic tree. The length of the branches in the phylogenetic tree 
implies the similarity in sequences between two aptamers. The shorter the branches length 
between two aptamers, the more similarity of sequences is in these aptamers. According to the 
phylogenetic tree, a few aptamers that branched closely were aligned together to obtain their 
consensus sequences. Among the aligned sequences, aptamers that are most similar to their 
consensus sequences were selected as representatives for binding analysis and Kd calculation.  
Out of all the analyzed aptamers, five aptamers (named M6, M16, M31, M40 and M43) have 
Kd values in the nanomolar range, indicating their high affinity towards MRCK. In contrast, 
they showed no cross-reactivity to inactive MRCK and thrombin, which was used as a 
negative control. This indicates that these aptamers are able to discern the conformational 
difference between active and inactive MRCK. The aptamer M6 was the best binder among 
these five aptamers. Fig. 3.8 shows the electropherograms of the binding profile of M6 to 




































Fig. 3.8 Binding analysis of M6. 100 nM of M6 was incubated with either 1 µM MRCK or 
1 µM of inactive MRCK or 1 µM of thrombin. Aptamer M6 alone was run as control. 
Complex peaks, circled in red, were only observed when M6 aptamer was incubated with 
MRCK, indicating the specific binding of M6 to MRCK. 
 
3.5.2 Modified non-SELEX 
Second and third enriched aptamer pools obtained from the modified non-SELEX 
method showed Kd values of about 1 µM. These two enriched aptamer pools were therefore 
cloned and sequenced for subsequent analysis. A total of 86 sequences were cloned and 
sequenced from these two enriched aptamer pools. All the sequences obtained were again 
aligned using the ClustalW2 programme. The phylogenetic tree generated from the multiple 
sequences alignment was shown in Fig. 3.9. In order to make sure that all the cloned aptamers 
were included in our analysis, 19 clusters were drawn from the phylogenetic tree as what is 
shown in Fig. 3.9. Every cluster contains aptamers with close similarity in DNA sequences. 
These 19 clusters were amplified and purified to form smaller pools of aptamers. Binding 
analysis using CE was subsequently performed on these 19 clusters. Out of these 19 clusters, 
four clusters (CL 2, CL 3, CL 6 and CL 18) gave positive results. A total of 22 aptamers were 
included in these four clusters and their individual binding affinities towards MRCK were 
tested. Among the 22 sequences, 9 of them have a total shift in aptamer peak when they were 
incubated with MRCK. In comparison to the free DNA peak of the control (DNA aptamers 
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alone without MRCK), a complete shift was observed. One aptamer F3.11 has the lowest Kd 
(109 nM) among the 9 aptamers The migration profile of F3.11 alone and F3.11 in the 
presence of MRCK is shown in Fig. 3.10. F3.11 together with M6 was eventually used in a 






































Fig. 3.9 Phylogenetic tree of aptamers from second and third enriched aptamer pools 
from novel non-SELEX. Clusters CL2, CL3, CL6 and CL18 are the clusters that gave 






























Fig. 3.10 Electropherograms of aptamer F3.11 alone and F3.11 together with MRCK. 
(A) Aptamer F3.11 alone was run on CE as a control. The free DNA aptamer peak of F3.11 
is indicated by green arrow. (B) 100 nM of aptamer F3.11 was incubated with 1 µM MRCK 
for 15 minutes before subjected for separation using CE. The whole aptamer peak, as 
indicated by red arrow, was shifted when MRCK bound to F3.11. The black arrow points at 
the peak of FITC which was used as internal standard to check for shift in aptamer peak.  
 
3.6 Affinity binding of aptamers M6 and F3.11 to MRCK was confirmed by an in vitro 
MRCK pull-down assay 
Two aptamers, namely M6 and F3.11 were found to have binding affinities to MRCK 
from a ssDNA library by using an original and a modified non-SELEX method respectively. 
The DNA sequences and the Kd for MRCK of M6 and F3.11 were summarized in Table 6. By 
using an alternative method to CE, binding affinities of these two aptamers were confirmed in 
an in vitro MRCK pull-down assay. In this in vitro MRCK pull-down assay, an incubation 
containing biotinylated aptamer, MRCK and poly-dIdC was prepared and biotinylated 
aptamer was pulled down in cold using a streptavidin column. The binding of the aptamer to 
MRCK, was scored by the presence of MRCK in the pull-down of biotinylated aptamer. Fig. 
3.11 shows the results of this in vitro MRCK pull-down assay for M6 and F3.11. For M6 
(Lane 2) and F3.11 (Lane 5), higher amounts of MRCK were detected in the eluents from 
streptavidin column. This is in contrast to the low amount of MRCK which was detected in 
the eluents from the streptavadin columns of negative control (Lane 1 and Lane 4), where no 
aptamer was present, or with scrambled DNA aptamer (Lane 3 and Lane 6). We therefore 
conclude that both M6 and F3.11 are able to pull-down MRCK in this in vitro system, 




Clone #  Aptamer sequence Kd / nM 
M6 AATGATAAACCACTGGTGAATCGCTCAAGTCAGTAGTAGG 125 
F3.11 CGAGCTGATGCGTGTCACCTCGTAGGACAGTCATCGAGGC 109 
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Fig. 3.11 Confirmation of the binding abilities of aptamers M6 and F3.11 to MRCK 
using an in vitro MRCK pull-down assay. Biotinylated ssDNA aptamer at a 
concentration of 0.4 µM was incubated with 2 µM MRCK and poly-dIdC (0.09-0.08 
µg/µl) in the cold for 2 hours. A streptavidin column was used to pull-down the 
biotinylated aptamer. Aptamer which has affinity to MRCK will be able to pull-down 
MRCK as well. The presence of MRCK in the pull-down was analyzed by western 
blotting (IB) with anti-6Histidines antibody. Input indicates the initial amount of MRCK 
in the incubation. Pull-down implies the amount of MRCK in the eluent that was released 
from the streptavidin column. Low amount of MRCK (background signal) was present in 
the pull-downs of control (lane 1 and lane 4), without aptamer, and aptamer with scramble 
sequences (lane 3 and lane 6). Aptamer M6 (lane 2) and F3.11 (lane 5) were able to pull-








The utilization of CE technology in SELEX for aptamer selection is a new attempt. 
Although certain areas of this approach are still required to be improved, the rapid selection 
process by CE-SELEX does offer a great advantage over the conventional method, making it 
a suitable technology for high-throughput screening. In this project, a screen for MRCK-
specific aptamers has been described as collaboration between our group and the Department 
of Chemistry in NUS. 
The selection of MRCK aptamers was first investigated with the optimization of the 
choices of buffer, its concentration and optimal pH for CE running. The CE running buffer 
composition is one of the major conditions that affect the detection of protein and aptamer-
protein complexes. It controls the ionization state of the protein and aptamer, and prevents 
adsorption of protein and DNA onto the capillary. The components of the buffer must be 
compatible with the formation and stabilization of the complexes (12) without affecting their 
specific association. Following this was the optimization of the selection buffer. Optimal 
NaCl concentration in the selection buffer is vital to prevent unspecific ionic interaction 
between the aptamers and targets, and to increase the stringency of the selection (7). Besides, 
magnesium is required to stabilize the aptamer secondary structure (2) and to promote the 
formation of complexes during migration. Buffer systems of extreme pH were avoided to 
prevent denaturation of aptamer and protein, or alteration of the functional groups crucial for 
interaction (12).  
CE-SELEX includes two types of partitioning proceses: nonequilibrium capillary 
electrophoresis of equilibrium mixtures (NECEEM) and equilibrium capillary electrophoresis 
of equilibrium mixtures (ECEEM). NECEEM-based non-SELEX was applied in an initial 
screening for MRCK aptamers. Non-SELEX omits the step of amplification and renders it to 
be more efficient. Owing to its fast and rapid process, non-SELEX was performed here. 
Simultaneously, some modifications were introduced into the original non-SELEX for the 
purpose to improve the quality of the screening process. 
 Before performing non-SELEX, concentration of the target protein needed to be 
54 
 
considered. The concentration of target protein used in the original non-SELEX was actually 
adapted from the protocol published by Berezovski M.V. et al. (7). For the modified non-
SELEX, serial concentrations of protein, from low to high (1 μM to 126 μM in Fig. 3.4B), 
were run on CE for target protein determination prior to MRCK aptamers screening. 
In the screening of these two methods, the Kd values of both the second and the third 
enriched aptamer pools were found to be quite similar (Table 4 and Table 5). This suggests 
that further selection did not actually improve the quality of selection. It is likely that having 
more rounds of selection in CE-SELEX may not actually mean one will collect aptamers with 
lower “bulk” Kd. In fact, a recent report has suggested that the Kd measurements of the 2nd 
enriched pool and the 3rd enriched pool were higher than the 1st enriched pool (64). There are 
a few reasons which may give rise to this observation. After the 2nd round of selection, 
almost all the aptamers in the pool possessed affinity to the target. When 3rd round of 
selection was performed, no significant improvement of binding could be observed due to the 
same sequences of aptamers, which were already present in the 2nd enriched pool, were 
selected. Moreover, contamination of the target protein or experimental error could also be 
possible in contributing to the lack of improvement in further rounds of selection. 
From the results of the original non-SELEX, aptamer (M6) with the lowest Kd of 125 
nM was selected. This aptamer was able to recognize conformation of active MRCK and not 
inactive MRCK. In an attempt to select aptamer with higher affinity to MRCK, the original 
non-SELEX protocol was revised and we realized that only part of the incubated DNA 
aptamers and targets was injected into CE for partition. The ssDNA library which was used 
here has 40 random bases and thus contains 1024 (404) different sequences. An injection of 
150 nL of 25 μM DNA library in the first round of selection contained only 1012 molecules of 
the DNA aptamer and many other sequences were missed out. Therefore, some adjustments 
were made to increase the loading size of CE. By performing ten injections and ten 
collections, we hope to increase the number of DNA molecules that would be subjected for 
partition. In this modified non-SELEX approach, however, the lowest Kd of aptamer (F3.11) 
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which was obtained is 109 nM. In fact, no significant improvement in MRCK binding affinity 
could be concluded from the modified approach. Although the Kd value of M6 (from the 
original non-SELEX) is comparable to the Kd value of F3.11 (from the modified non-SELEX), 
the MRCK binding profiles of these two aptamers were different. Many complex peaks were 
observed for M6-MRCK complex while a total shift in aptamer peak was observed for F3.11. 
These observations suggest that M6 might interact with MRCK at different sites and thus 
results in M6-MRCK complexes with different charge-to-mass ratio. Difference in charge-to-
mass ratio consequently affects the retention time of the complexes. In contrast, aptamer 
F3.11 might bind to MRCK at a more consistent manner and caused a complete shift in 
aptamer peak.  
 As mentioned previously, the interaction of M6 and F3.11 to MRCK was also further 
confirmed by in vitro MRCK pull-down assay. Aptamer M6 and F3.11 could precipitate equal 
amount of MRCK in the pull-down suggesting M6 and F3.11 have similar affinity to MRCK 
which is consistent with their calculated Kd values.  
The main focus of the first part of this project, that is MRCK aptamers screening, was 
actually more for the purposes in developing CE-SELEX method and to validate the 
feasibility of using DNA aptamers as molecular probes for protein recognition. The two 
selected aptamers, M6 and F3.11, were subsequently sent to our collaborator at the 
Department of Chemistry, NUS, for the design of molecular aptamer beacon (MAB, described 
in Section 1.1.2). In addition to in vitro studies, we have also tried to microinject into HeLa 
cells for MRCK interference and cytoskeletal organization studies. The preliminary data 
showed that M6 did not exhibit strong binding to endogenous MRCK when introduced into 
HeLa cells as majority of the aptamer was detected in the cell nucleus (data not shown). From 
these preliminary studies, there are three main reasons which hindered us from carrying out 
further investigation. First, the aptamers fluoresce by themselves even without binding to the 
targets and this is thus unsure as whether they bind to the real targets. Second, ssDNA 
aptamer have high affinity to nuclear DNA and RNA (61, 82). They tend to migrate into cell 
nucleus which would attenuate the amount of aptamers available for targets detection in the 
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cytosol. Third, the binding affinity of aptamer M6, with Kd value of 125 nM, may not be high 
enough and thus may affect the detection limit in cell staining. All these have thus precluded 
more functional studies on M6 aptamer, including the study on MRKC inhibitory effects.  
In our initial proposal, we also planned to look for aptamers that can inhibit MRCK 
activity. Owing to the tendency of aptamer’s association with the cellular RNA and DNA 
which may reduce its efficacy, inhibition of MRCK with the use of chemical compounds was 
also concurrently pursued. The findings are described in the next chapter.  
57 
 
Chapter 4  
Screening of Selective Inhibitors for Myotonic Dystrophy Kinase-Related Cdc42 
Binding Kinase (MRCK) by Chemical Inhibition 
 
4.1 Introduction 
MRCK was discovered to be the key regulator of myosin activity underlying cell 
protrusion and neurite outgrowth (16, 51) and together with ROK and MLCK (36) they 
regulate in vivo phosphorylation of myosin light chain (MLC) and the phosphatase inhibitory 
motif (PIM) of myosin phosphatase. Besides, MRCK is also engaged in the lamellar 
retrograde flow that may direct nuclear movement in migrating cells (31). It was found that 
MRCK exists as a tripartite complex containing LRAP35a, a Leucine repeat adaptor protein, 
and MYO18A. This MRCK-LRAP35a-MYO18A complex plays a major role in the assembly 
of the lamellar actomyosin flow bundles that are important for persistent membrane 
protrusion (88). Various means of inhibiting MRCK have been used, including introduction 
of siRNA and dominant negative constructs into the cells. However, the most effective and 
rapid way of inhibition would be the use of a chemical compound that can cause immediate 
inhibition on MRCK kinase activity. 
High-throughput screening for specific inhibitors for various kinases have been 
widely carried out and found to be successful. For example, JX401 was identified as a 
mitogen-activated protein kinase p38alpha via a high-throughput screen using yeast cells(28). 
In this project, an in vitro screening method using Kinase-Glo Luminescent kinase assay was 
applied to facilitate the screening process of MRCK inhibitors. In brief, MRCK kinase 
reaction was performed in the presence of a compound and the remaining ATP in the solution 
after the kinase reaction was detected by the addition of a Kinase-Glo Luminescent Reagent 
which converts ATP to luminescent signal (Fig. 4.1A). Therefore, the release of luminescent 
signal is inversely related to kinase activity.  
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4.2 MRCK enzymatic kinetic studies 
Before the actual screening process, some enzymatic kinetic studies on MRCK were 
done in order to obtain an optimal condition to carry out MRCK kinase reaction for inhibitors 
screening. Fig. 4.1B shows the sigmoidal kinetic curve of MRCK kinase activity.  As reported 
previously, there is a relationship between MRCK N-terminus-dependent kinase domain 
dimerization and kinase activity (87). Dimerization of MRCK N-terminus and trans-
autophosphorylation of key residues within the activation loop and the extended hydrophobic 
phosphorylation motif are required for MRCK activation.  As shown in Fig. 4.1B, MRCK is 
not enzymatically active at low concentrations (<0.01 µM). A critical concentration of MRCK 
is required to achieve dimerization and activation of MRCK. Upon dimerization, MRCK 
activity resembles a normal progress curve for a first order enzymatic reaction, i.e. the 
production rate is approximately linear at the initial stage for a short period and the rate 
gradually slows down as the reaction proceeds when the substrate is consumed. Furthermore, 
according to the time course study of a serial concentration of MRCK as shown in Fig. 4.1C, 
the kinetic curve of 0.05 µM of MRCK is linear within the first 30 minutes. As a result, 0.05 
µM MRCK and 20 minutes kinase reaction time are chosen for MRCK inhibitors screening as 
MRCK activity is within the linear range in terms of enzymatic rate and reaction time. 
Other than MRCK concentration and kinase reaction time, ATP concentration and 
substrate concentration are the other two factors which need to be determined. The detection 
window of ATP level of the Kinase-Glo assay is from 0 to 10 µM. There is a linear 
relationship between the luminescent signal and the amount of ATP in the kinase reaction 
from 0–10 μM using this assay. 5 µM of ATP is the minimum ATP concentration (4) that is 
normally used for kinase assays and this concentration is at the linear portion of the detection 
window of Kinase-Glo assay. The Km for ATP for MRCK was estimated to be approximately 
1.5 µM (Fig. 4.1D). As 5 µM of ATP is near to the Km for ATP for MRCK and the ATP 
detection ability of the Kinase-Glo reagent is also quite sensitive around this region, 5 µM 
ATP is thus ideal for kinase assay. For the substrate, phosphatase inhibitory motif (PIM) of 
myosin-binding subunit was used as the substrate and the Km for PIM for MRCK was 
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predicted to be about 1 µM in Fig. 4.1E. 5 µM of PIM, which is higher than the Km for PIM, 





















Fig. 4.1 Enzymatic kinetic studies on MRCK. (A) The Kinase-Glo assay reactions. Kinase 
reaction was conducted at room temperature for 20 minutes. The level of ATP remaining after 
the kinase reaction was detected by adding Kinase-Glo Luminescent Reagent. ATP acts as a 
substrate for Kinase-Glo Luciferase in the reagent to catalyze the mono-oxygenation of luciferin. 
The luciferase reaction produces one photon of light per turnover. (B) The sigmoidal kinetic 
curve of MRCK activity. (C) Time course study of MRCK activity at different MRCK 
concentrations. The red box marks out the linear range of MRCK activity at 0.05 µM in the first 
30 min. (D) The initial reaction velocity, Vo, of 0.05 µM and 0.2 µM MRCK was plotted against 
ATP concentration for the estimation of ATP Km for MRCK. (E) The Vo of 0.05 µM and 0.2 µM 
MRCK, were plotted against PIM substrate concentration for the estimation of the substrate Km 





4.3 MRCK inhibitors screening and discovered chelerythrine chloride as a potential 
MRCK inhibitor  
In the initial screen, approximately 155 chemical compounds, among which most of 
them are known kinase inhibitors, were screened initially in order to obtain a common 
chemical structure that can inhibit MRCK. From the screening results shown in Fig. 4.2A, 
luminescent signal released from a chemical compound called chelerythrine chloride 
(che/chelerythrine; 10 μM) was close to the negative controls, indicating that no active 
MRCK was present to consume ATP. Chelerythrine produced the highest inhibition among all 
the screened compounds. In the functional studies of selected chemicals, more investigation 
was focus on chelerythrine but not INCA-6 because its effect on MRCK is more direct and 
promising. Although INCA-6 seemed to be an effective inhibitor from the in vitro screening, 
it did not produced obvious in vivo inhibitory effect when HeLa cells were treated with 10 
μM of INCA-6 for 1 hr (data not shown). One possible explanation on the inhibitory 
mechanism of INCA-6 is that it may block the substrate recognition site of MRCK but not the 
catalytic site. This deduction is according to its known inhibitory action on calcineurin where 
INCA-6 interrupts the interaction between calcineurin and its substrate, nuclear factor of 
activated T cells (NFTA) (75). However, this still does not fully explain why INCA-6 does not 
affect active MRCK in vivo localization because lamellar and cell central localization of 
active MRCK depends on both its catalytic activity and substrate recognition ability. MRCK 
localization should be perturbed when MRCK has no activity and cannot recognize its 
substrate. As the real working mechanism of INCA-6 is still unknown, we did not carry out 
further functional studies on INCA-6. 
Chelerythrine (Fig. 4.2B, 1) was reported in 1990 by Herbert’s group to be a potent 
and specific inhibitor for PKCα with an IC50 of 660 nM (32). It has a wide range of biological 
activities, including antiplatelet, anti-inflammatory, antibacterial and antitumor effects. It can 
also activate MAPK (mitogen-activated protein kinases) pathways which is independent of 
PKC inhibition. Moreover, chelerythrine can inhibit the binding of BclXL to Bak at IC50=100 
μM to stimulate apoptosis (8, 100). However, a more recent study was not able to confirm the 
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inhibitory effect of chelerythrine on PKC (50). It is of our interest to compare the inhibitory 
effects of this compound on the kinase activity of MRCK, PKC and other MRCK-related 
kinases. 
A second screen was also carried out with another 19 compounds that are structurally 
similar to chelerythrine. Of these, Sanguinarine (Fig 4.2B, 2) which has the most similar 
structure as chelerythrine can also inhibit MRCK. Fig. 4.2D shows that both chelerythrine and 
sanguinarine inhibited MRCK activity in a concentration-dependent manner. MRCK activity 
was completely inhibited at 2 µM of both chelerythrine and sanguinarine. The MRCK 
inhibitory property of chelerythrine and sanguinarine is probably due to their highly similar 
structure. In contrast, Y-27632, a ROK inhibitor, has no inhibitory effect on MRCK activity 
at this concentration. Moreover, a compound no. 15 (Fig. 4.2C) from the second screen can 
also perturb MRCK localization in HeLa cells (Fig 4.2E) but it has no inhibitory effect on 
MRCK activity in an in vitro kinase assay (data not shown). These results suggested that its 
target is not MRCK and it probably inhibits another target along the pathway of MRCK. 
Therefore, more investigation should be carried out to search for the actual target of 



































Fig. 4.2 MRCK inhibitors screening. (A) Chemical compounds were screened in duplicates 
in a 384-well format. Two rows at the sites, as indicated, were positive controls (with MRCK 
but no compound) and negative controls (without MRCK and compound) respectively. The 
two highest hits were obtained from chelerythrine chloride and INCA-6, which are boxed in 
red. (B) and (C) The chemical structure of chelerythrine chloride (1), sanguinarine (2) and 
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Compound no. 15 
1 μM  
30 min 
E Anti-MRCK Anti-Myo IIa 
Fig. 4.2 –continued 
(D) Serial concentrations of che, sanguinarine, and Y-27632, were tested on MRCK activity 
using non-radioactive kinase assay. MLC2 was used as substrate in the kinase assay. The 
phosphorylation of MLC2 was detected by western blot with anti-pS19 MLC2 antibody. 
Che and sanguinarine, but not Y-27632, can inhibit the activity of MRCK in a dose-
dependent manner. (E) Effect of compound no. 15 on MRCK localization in HeLa cells. 
Cells were co-stained with anti-MRCK and anti-Myosin IIa antibodies. Treatment of 
compound no. 15 on HeLa cells at 1 μM for 30 min was able to perturb MRCK localization. 
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4.4 Substrate specificity and phosphorylation of MRCK-related kinases 
Various recombinant protein kinase including MRCK, ROK, DMPK, CRIK, MLCK, 
PAK, PKA and PKC were expressed and purified, and their activities in phosphorylating 
substrates such as PIM and MLC2 were tested and compare. Analyses of MLC2 
monophosphorylation on S19 alone or diphosphorylation on T18/S19 were achieved by the 
use of specific anti-pS19 MLC2 and anti-ppT18/S19 MLC2 antibodies respectively. 
As shown in Fig. 4.3B, among all the tested kinases, CRIK was inefficient in 
phosphorylating PIM. The main function of CRIK is in the regulation of contractile process in 
cytokinesis (54) that its activity correlates with an increase in diphosphorylated MLC2 level 
in vivo during cytokinesis (103). Its inability to phosphorylate PIM suggests that its regulation 
on diphosphorylation of MLC2 during cytokinesis does not involve inhibition of myosin 
phosphatase. In contrast, PIM was effectively phosphorylated by MRCK, ROK, DMPK, PAK 
and PKA. These in vitro results suggest that all these kinases have the potential to inhibit 
myosin phosphatase and thus cause phosphorylated myosin phosphatase in preserving cellular 
MLC2 phosphorylation. In fact, ROK’s action on MLC2 phosphorylation had been shown to 
involve myosin phosphatase inhibition (1). In the case of MLC2 phosphorylation, all kinase 
except DMPK and PKA could phosphorylate MLC2. Earlier reports shown that myosin II 
with diphosphorylated MLC2 has a higher actin-activated Mg2+-ATPase activity than that 
with monophosphorylated MLC2 (37, 96). In addition, myosin II with diphosphorylated 
MLC2 resulted in enhanced tension on stress fibers (63). As ROK is implicated in the 
contraction of actomyosin at the cell rear during cell migration and CRIK in the contractile 
ring formation in cytokinses, ROK and CRIK induce diphosphorylation of MLC2 to generate 
a higher mechanical force at the cell rear and cell center respectively for detachment during 
cell movement and to pull the two cells apart during cytokinesis. In contrast, MLC2 
phosphorylation on S19 by MRCK has been shown to localize more to the cell front. This 
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Fig. 4.3 Substrates, PIM and MLC2, specificities and phosphorylation studies for 
MRCK and MRCK-related kinases. (A) Radioactive kinase assay supplement with [γ-
32P]ATP was used to check the ability of MRCK (lane 1), ROK (lane 2), DMPK (lane 3), 
CRIK (lane 4), PAK (lane 6) and PKA (lane 7) to phosphorylate PIM. Phosphorylated PIM 
(32P-PIM) containing radioactive signal was detected when exposed onto an X-ray film 
indicating that PIM is a substrate for that particular kinase. (B) Non-radioactive kinase assay 
and western blot using anti-pS19 MLC2 and anti-ppT18/S19 MLC2 antibodies were carried 
out to detect the phosphorylated residue(s) on MLC2 by MRCK (lane 1), ROK (lane 2), 
DMPK (lane 3), CRIK (lane 4), MLCK (lane 5), PAK (lane 6) and PKA (lane 7). MRCK, 
ROK, MLCK and PAK can phosphorylate S19 of MLC2 while only ROK and CRIK are able 
to phosphorylate MLC2 at T18/S19. A lower amount of MLC2 can be phosphorylated by 
MLCK at T18/S19.  
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4.5 Chelerythrine chloride inhibits MRCK specifically and only inhibits ROK and 
CRIK at a higher concentration 
The selectivity of chelerythrine, using 5 µM and 10 µM as cut off points, was studied 
on ROK, DMPK, CRIK, MLCK, PAK, PKA and PKCα (Fig 4.4). Expression of kinases was 
confirmed using western blot analysis with anti-6 histidine and anti-GST antibodies. The 
kinase activities of some purified enzymes were also tested with their respective inhibitors 
avalaible: like Y-27632 for ROK, ML-7 for MLCK, H89 for PKA and staurosporine for 
PKCα. Chelerythrine at 5 µM was found to inhibit MRCK activity almost completely but was 
unable to inhibit ROK, DMPK, CRIK, MLCK, PAK, PKA and PKCα. However, decreases in 
ROK and CRIK kinase acitivities were only observed at 10 µM. Chelerythrine only has slight 
inhibitory effect on PKCα at 10µM, this means that chelerythrine does not effectively inhibit 
PKCα in agreement with the latest findings (18, 50). Among Y-27632, staurosporine, ML-7 
and H89, only 50 nM of staurosporine was found to partially inhibit MRCK among the tested 
inhibitors. The inhibitory effect of chelerythrine on ROK and CRIK was further investigated 










































(a) 2% DMSO 
(b) 5 µM che 
(c) 10 µM che 
(d) 5 µM Y-27632 
(e) 50 nM staurosporine 
(f) 20 µM ML-7 




Fig. 4.4 Selectivity studies of chelerythrine on MRCK, ROK, CRIK, MLCK, PAK, DMPK, 
PKA and PKCα. Radioactive kinase assay was used to check the inhibitory effects of 
chelerythrine and other kinase inhibitors on MRCK-related kinases. The kinases used in each 
kinase assay were detected by western blot using anti-6 histidines or anti-GST antibodies, 
depends on the protein tag. The tested chemicals included 2% DMSO as control (lane a), 5 µM 
che (lane b), 10 µM che (lane c), 5 µM Y-27632 (lane d), 50 nM staurosporine (lane e), 20 µM 
ML-7 (lane f) and 0.5 µM H89 (lane g). 
4.6 Kinetics of chelerythrine chloride inhibition of MRCK  
In Section 4.3, chelerythrine was shown to inhibit MRCK activity on phosphorylation 
of MLC2 in a concentration-dependent manner. The inhibition was also comparable to 32P-
ATP-based kinase acitivity wih PIM as substrates (Fig. 4.5A). Previously, it has been shown 
that Y-27632 inhibited ROK-induced contraction of rabbit aortic strips with a reported IC50 of 
0.7 µM (94). In comparison, the IC50 of chelerythrine on MRCK was found to be 
approximately 0.86 µM by the in vitro kinase assay (Fig. 4.5B) whereas the IC50 values of 
chelerythrine on ROK and CRIK were estimated to be about 8.6 µM and 6.4 µM respectively 
(Fig. 4.5C). Like MRCK, ROK and CRIK share sequence homology in the kinase domain and 
substrate specificity, such as PIM and MLC2. Therefore, chelerythrine was expected to 
exhibit some degree of inhibition both on ROK and CRIK. Our results show that the IC50 
values on these two kinases are almost 10-fold higher than that for MRCK. Chelerythrine is 
therefore considered to be more specific towards MRCK as it will only inhibit ROK and 
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Fig. 4.5 The calculation of IC50 for chelerythrine for MRCK, ROK and CRIK. (A) 
Radioactive kinase assay using PIM as substrate and supplement with [γ-32P]ATP was 
carried out to calculate the IC50 of chelerythrine on MRCK. ROK activity inhibition 
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(B) IC50 for chelerythrine for MRCK was calculated from the plotted sigmoidal curve. The 
IC50=0.861 µM is at the 50% of kinase activity, which is indicated in the graph. All data 
are mean ± S.E. of triplicate determinations. (C)Radioactive kinase assay was performed 
by using PIM as substrate for ROK and MLC2 for CRIK. Che with concentrations at the 
range of 2.5 µM to 10 µM were tested on ROK and CRIK kinase activity to calculate the 
IC50 values (D) IC50 values for chelerythrine for ROK and CRIK were calculated to be 
about 6.44 µM and 8.6 µM from the plotted curves.  
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4.7 Chelerythrine chloride treatment can perturb endogenous MRCK localization in 
HeLa cells 
The effects of chelerythrine, H89, ML-7 and Y-27632 on MRCK localization in 
HeLa cells were examined. Endogenous MRCK is mainly localized in the lamella and cell 
center (88), showing significant co-localization with specific myosin networks as revealed by 
anti-pS19 MLC2 antibody (Fig. 4.6). Treatment with 5 µM of chelerythrine for 1 hour results 
in perturbation of MRCK localization and co-localization with the phosphorylated MLC2. 
This phenomenon was observed to a lesser extent with 2.5 µM of chelerythrine. In contrast, 
other kinase inhibitors such as H89, ML-7 and Y-27632, did not affect MRCK localization 
reflecting the specific effect of chelerythrine on MRCK inhibition. Chelerythrine was 
reported to induce a dose-dependent decrease in the cell viability with IC50 of 2.6 µM after 4 
hours of treatment (99). Thus, by reducing chelerythrine concentration and duration of the 
treatment, induction of apoptosis by chelerythrine can be avoided. 
 As mentioned previously, ROK is able to induce diphosphorylation of MLC2 at both 
T18 and S19 (Fig. 4.3B). It is expected that a loss of diphosphorylation would indicate a lack 
of ROK activity. In order to check if chelerythrine would cross-inhibit ROK and CRIK in 
vivo, cells were probed with anti-ppT18/S19 MLC2 antibody. As shown in Fig. 4.7, cells 
treated with ROK inhibitor, Y-27632, showed normal MRCK localization but the level of 
diphosphorylated MLC2 was greatly reduced. As ROK is involved in the formation of stress 
fibers, ROK inhibition also caused the loss of actin bundles at the cell center, which is shown 
in the decrease of phalloindin staining. In contrast, the level of diphosphorylated MLC2 was 
not affected in the cells treated with chelerythrine. These results indicate that treatment with 5 
µM chelerythrine does not affect cellular ROK activity. The cross-inhibition of chelerythrine 
on CRIK was not taken in consideration as the main function of CRIK is involved in 





































1 µM H89 1 
hr 
10 µM ML-7 
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5 µM         
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30 min 
Fig. 4.6 Localization of endogenous MRCK and phospho-S19 MLC2 in HeLa cells 
treated with chelerythrine and other kinase inhibitors. HeLa cells were treated with 
DMSO as control, 5 µM chelerythrine (1hr), 2.5 µM chelerythrine (1 hr), 1 µM H89 (1 hr), 10 
µM ML-7 (1 hr) and 5 µM Y-27632 (30 min).Cells were fixed and stained with anti-MRCKα 
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Fig. 4.7 Effects of chelerythrine and Y-27632 on MRCK. HeLa cells were either treated 
with DMSO as positive control, 5 µM Y-27632 as negative control, or 5 µM chelerythrine. 
The cross-inhibition of chelerythrine on ROK was examined by doing cell staining with 
anti-MRCKα antibody, anti-ppT18/S19 MLC2 antibody and phalloidin.  
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4.8 Chelerythrine chloride reduces cell migration in U2OS wound healing assay 
MRCK has been primarily shown to play an important role in cell migration (88). 
Therefore, the effect of chelerythrine on cell migration was examined by performing a wound 
healing assay on U2OS cells. After a wound was made on fully confluent U2OS cells, 
medium containing either DMSO or 2.5 µM chelerythrine was added. As shown in Fig. 4.8B, 
the U2OS cells under 2.5 µM chelerythrine treatments migrated slower than the control. Fig. 
4.8A depicts the pictures of cell migration in wounded U2OS cells between non-treated and 
chelerythrine-treated cells. Cells appear to migrate faster and further under normal condition 
while the migration distance of chelerythrine-treated cells were obviously delayed. Our data 
















Fig. 4.8 Effect of chelerythrinee on cell migration. (A) U2OS cells were grown to 100% 
confluent onto coverslips and the cells were scratched lightly to generate a wound. Cells 
were incubated with fresh medium supplement without or with 2.5 µM chelerythrine for 4 
hours. The process of cell migration during these 4 hours was recorded. The pictures of the 
recovery of the wounds at 1 hr and 4 hr after the wounds were shown here. (B) The distances 
of cell migration under these two treatments were calculated for statistical analysis. About 30 
cells were calculated from each treatment and the data was obtained from the mean ± S.E. of 
the calculated cells from three different sets of experiments. * student t-test p-value<0.05 
Wound healing assay






































In this section a specific MRCK inhibitor, chelerythrine chloride, was discovered via 
a chemical compounds screening. Prior to the screening, MRCK enzymatic kinetics were 
studied. The measurement of MRCK enzymatic kinetics activities apparently revealed some 
supportive evidences on the previous findings that MRCK catalytic activity is dependent on 
kinase domain dimerization and trans-autophosphorylation events. MRCK has low kinase 
activity at low enzyme concentrations (<0.01 μM) presumably due to the lack of dimer 
formation driven by concentration-dependent process. As the concentration increases, 
dimerization of MRCK could then occur more readily and this would render the kinase to be 
active through trans-autophosphorylation as previously reported (87). A similar activation 
mechanism which requires dimerization and trans-autphosphorylation events have also been 
disclosed for the two MRCK-related kinases, ROK and DMPK (52).  
Substrate specificity profiles of MRCK, ROK, DMPK, CRIK, PAK and PKA were 
initially studied in this project. These studies are important as the substrate specificity of a 
kinase may reflect the cellular functions of the kinase. MRCK, ROK and MLCK are the three 
known MLC2 kinases which are involved in different pathways at different locations and 
regulate contraction of different networks of actomyosin. In these studies, MRCK, MLCK 
and PAK were found to be able to monophosphorylate MLC2 at S19 while ROK and CRIK 
diphosphorylate MLC2 at both T18 and S19. Interestingly it has been reported that 
monophosphorylated MLC2 was found to localize more towards the protrusive region and 
diphosphorylated form mainly at the posterior end (46, 78). Our data coincides with the 
findings that MRCK regulates the myosin II in the lamellar filaments while myosin II 
regulation by MLCK is in the lamellipodia (88, 91). Phosphorylation of MLC2 by PAK has 
also been reported but its exact role has yet to be determined (92). As for ROK, its ability in 
diphosphorylating MLC2 conforms well to its function in causing tail contraction at the 
retracting cell rear (45, 98). Besides, diphophorylation of MLC2 by CRIK is involved in the 




Biochemical analysis of MRCK inhibition showed that structurally related 
compounds chelerythrine and sanguinarine inhibited MRCK in a concentration-dependent 
manner, similar to the effect of Y-27632 on ROK. The two inhibitors differ only at the R1 and 
R2 side chains. Based on their similar inhibition profile on MRCK, other compounds which 
have similar chemical structure to chelerythrine might also be able to inhibit MRCK. 
Therefore, screening of related compounds with similar structure or modified side chains 
would facilitate the search of a more potent MRCK inhibitor. The screening of some 
structural related compounds with fused BCD rings had not yielded any positive results, 
suggesting that other structural design involving ABC rings may be more desirable (Fig. 4.2B 
and C). 
Although chelerythrine was first discovered to be a potent and selective inhibitor of 
PKCα (32), it was however disapproved by later studies (8, 18). Furthermore, in agreement 
with the later studies, our data also shown that chelerythrine has no inhibitory effect on PKC. 
Chelerythrine has weaker inhibition on ROK and CRIK and only inhibits these two kinases at 
much higher concentrations for MRCK. The IC50 of chelerythrine for MRCK was estimated 
to be 0.86 μM but was found to be about ten times higher for ROK and CRIK (8.6 μM and 
6.4 μM respectively). Chelerythrine is therefore a more specific inhibitor for MRCK than 
ROK and CRIK. This is in contrast to Y-27632 which is more specific to ROK and can only 
inhibit MRCK at a higher concentration.  
In addition, we also showed that chelerythrine can inhibit MRCK activity in vivo and 
affect its localization in HeLa cells. We also observed that chelerythrine could result in a 
reduction in cell migration speed as shown in a wound healing assay. This MRCK inhibitory 
property of chelerythrine can also be exploited as a useful tool for functional studies of 
MRCK. Besides, it could also be useful in structural analysis on MRCK kinase domain. It 
will be interesting to find out if this compound might also be beneficial in inhibiting 
metastasis of cancerous cells in future due to its ability in affecting cell migration. This study 




A new technique named CE was utilized to perform SELEX in the screening of 
MRCK aptamers. Optimal conditions for carrying out MRCK aptamers selection were 
determined through method development on CE-SELEX. In the optimization, CE running 
buffers, phosphate buffer (pH 7) and borate buffer (pH 9), were used to visualize and compare 
the retention time and migration pattern of MRCK. NaCl concentrations were optimized and 
the selection buffer with 50 mM Tris, 50 mM NaCl and 5 mM MgCl2 was employed to obtain 
MRCK-aptamer complex peaks. When borate buffer was used as CE running buffer, the 
retention time of MRCK was found to be at the region of 8-9 minutes while the retention time 
of DNA was at 11-12 minutes. An original non-SELEX was used in the initial screen and the 
best candidate selected, aptamer M6, has an affinity of 125 nM. This aptamer has the ability 
of detecting the active MRCK but not the inactive MRCK. In the attempt to achieve the 
purpose of obtaining strong MRCK binders, a modified non-SELEX approach was introduced 
and carried out in the second screen. The best binder, aptamer F3.11 has a Kd value 109 nM. 
No significant improvement in MRCK binding affinity could be concluded from the modified 
approach. Meanwhile, MRCK interactive property of these two aptamers, M6 and F3.11, 
were further confirmed in an in vitro MRCK pull-down assay. When tested on live cells, 
however, these aptamers were found to be trapped in the cell nucleus and did not appear to 
have specific localization to MRCK in vivo. Further modification on the DNA structure of the 
aptamers will therefore be helpful to overcome this problem for in vivo use in future. 
In addition to MRCK aptamers screening, MRCK inhibitors screening from a total of 
approximately 170 chemical compounds was carried out concurrently. From the result of this 
chemical screening, Chelerythrine chloride was identified and discovered to have MRCK 
inhibitory activity with its IC50 of 0.86 µM. Sanguinarine, structurally similar to chelerythrine, 
also displayed MRCK inhibition in a concentration-dependent manner parallel to 
chelerythrine. In the study of chelerythrine’s specificity to MRCK and other kinases, 
chelerythrine exhibited cross inhibitory effect on the related kinases ROK and CRIK but with 
higher IC50 values of 8.6 µM and 6.4 µM respectively. In the subsequent in vivo cell studies, 
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the co-localization profile of both MRCK and the corresponding monophosphorylated 
Myosin Light Chain 2 (MLC2) at Serine 19 was readily perturbed by chelerythrine treatment 
on HeLa cells at a concentration of 5 µM for 1 hour. In contrast, diphosphorylation of MLC2 
at Threonine 18/Serine19 was not affected by chelerythrine indicating its specificity toward 
MRCK. Moreover, a delay in cell migration was observed when U2OS cells were treated with 
2.5 µM chelerythrine in a wound healing assay. It is concluded that chelerythrine is a 
moderately specific inhibitor for MRCK. Further modifications on the chemical structure of 
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 Modern SELEX 
 
Conventional SELEX 
  CE-SELEX Non-SELEX 
 Similarities 
 
(1) In vitro method used to select DNA/RNA which have binding affinity to a particular target protein 
 
 
(2) Selection starts from a random sequences of DNA/RNA library 
  
 




  Conventional SELEX CE-SELEX Non-SELEX 
(1) Amplification of selected 
DNA/RNA  
Required between each round of 
selection 
Required between each round of 
selection 
Not required 
(2) Rounds of selection required Average 8-12 rounds 3-4 rounds 3-4 rounds 
(3) Duration of whole selection 
process 
Month(s) Weeks Days 
(4) Amount of target protein High (in terms of μg) Low (in terms of ng) Low (in terms of ng) 
(5) Volume of sample during 
selection 
Microliter Nanoliter Nanoliter 
(6) Fashion of technique(s) 
performance 
Manual Manual and automated Can be fully automated 
(7) Blocking step before selection Required Not required Not required 
 
Table 8. The similarities and differences of conventional SELEX, CE-SELEX and Non-SELEX. 
 84 
